var title_f32_63_33776="Hypopigmented sarcoidosis";
var content_f32_63_33776=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F74163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F74163&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hypopigmented sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hypopigmented sarcoidosis. Discrete, hypopigmented macules and patches are present on the trunk. Some lesions demonstrate central papules, which resemble the configuration of a fried egg.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_63_33776=[""].join("\n");
var outline_f32_63_33776=null;
var title_f32_63_33777="Stool sample 5";
var content_f32_63_33777=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66192&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66192&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stool sample 5",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 348px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_63_33777=[""].join("\n");
var outline_f32_63_33777=null;
var title_f32_63_33778="Patient information: Bone cancer (The Basics)";
var content_f32_63_33778=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"18\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?26/48/27394\">",
"         Patient information: Chondrosarcoma (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?31/3/31794\">",
"         Patient information: Ewing sarcoma (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?17/27/17842\">",
"         Patient information: Hair loss from cancer treatment (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?1/40/1667\">",
"         Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?0/36/579\">",
"         Patient information: Managing pain when you have cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?25/21/25939\">",
"         Patient information: Medical care during advanced illness (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?18/57/19346\">",
"         Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?39/32/40450\">",
"         Patient information: Radiation therapy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?29/4/29762\">",
"         Patient information: When your cancer treatment makes you tired (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Bone cancer (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/bone-cancer-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H5325141\">",
"      <span class=\"h1\">",
"       What is bone cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Bone cancer happens when normal cells in the bone change into abnormal cells and grow out of control. This article discusses cancer that starts in the bone. But people can also get cancer in their bones after cancer from another part of the body spreads to the bones.",
"     </p>",
"     <p>",
"      There are different types of bone cancer, depending on the cells involved. The most common type is osteosarcoma. Other common types of bone cancer are chondrosarcoma and Ewing sarcoma.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5325156\">",
"      <span class=\"h1\">",
"       What are the symptoms of bone cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Bone cancer usually causes pain and swelling in the area of the cancer. The pain can come and go, but it usually gets worse over weeks to months. The pain is sometimes worse at night and with exercise. Some people with bone cancer might also see or feel a lump on their bone or in the tissues around the bone.",
"     </p>",
"     <p>",
"      All of these symptoms can also be caused by conditions that are not bone cancer. But if you have these symptoms, tell your doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5325171\">",
"      <span class=\"h1\">",
"       Is there a test for bone cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will first order an X-ray of your bone.",
"     </p>",
"     <p>",
"      If the X-ray shows that you likely have bone cancer, you will have other tests. These will probably include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        An imaging test, such as an MRI or CT scan, of the area with the cancer &ndash; An imaging test creates pictures of the inside of the body.",
"       </li>",
"       <li>",
"        A full-body bone scan or other imaging test, to check for bone cancer in other parts of your body",
"       </li>",
"       <li>",
"        A biopsy &ndash; This is a procedure in which a doctor removes a sample of the cancer. Then another doctor looks at the sample under a microscope.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5325186\">",
"      <span class=\"h1\">",
"       What is cancer staging?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Cancer staging is a way in which doctors find out if a cancer has spread past the layer of tissue where it began, and, if so, how far.",
"     </p>",
"     <p>",
"      The right treatment for you will depend a lot on the type of bone cancer you have, its stage, and your other medical problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5325201\">",
"      <span class=\"h1\">",
"       How is bone cancer treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Depending on the type of bone cancer, treatment includes 1 or more of the following:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Surgery &ndash; In general, surgery is the main treatment for bone cancer. The type of surgery you have depends on where your cancer is and how big it is. In most cases, surgeons do &ldquo;limb-sparing&rdquo; surgery. This is when the surgeon removes the cancer without removing the arm or leg where the cancer is growing. Depending on the type of surgery, the doctor might need to &ldquo;rebuild&rdquo; part of a bone after surgery.",
"        <br/>",
"        <br/>",
"        Sometimes, when bone cancer is growing in an arm or leg, surgery involves amputation. This is when the surgeon removes the arm or leg along with the cancer. After an amputation, some people use a prosthesis, which is a man-made arm or leg.",
"       </li>",
"       <li>",
"        Chemotherapy &ndash; Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells. Most people with bone cancer have chemotherapy before and after their surgery.",
"       </li>",
"       <li>",
"        Radiation therapy &ndash; Radiation kills cancer cells. Doctors might use radiation when people can&rsquo;t have surgery or when all of the cancer can&rsquo;t be removed safely with surgery.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5325216\">",
"      <span class=\"h1\">",
"       What happens after treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After treatment, your doctor will check you every so often to see if the cancer comes back. Follow-up tests can include exams, blood tests, chest X-rays, and imaging tests.",
"     </p>",
"     <p>",
"      You should also watch for the symptoms listed above. Having those symptoms could mean your bone cancer has come back. Tell your doctor or nurse if you have any symptoms.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5325231\">",
"      <span class=\"h1\">",
"       What happens if my bone cancer comes back or spreads?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your bone cancer comes back or spreads, you might have more surgery, radiation, or chemotherapy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5325246\">",
"      <span class=\"h1\">",
"       What else should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;It&rsquo;s important to follow all of your doctor&rsquo;s instructions about visits and tests. It&rsquo;s also important to talk to your doctor about any side effects or problems you have during treatment.",
"     </p>",
"     <p>",
"      Getting treated for bone cancer involves making many choices, such as what treatment to have. Always let your doctors and nurses know how you feel about a treatment. Any time you are offered a treatment, ask:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        What are the benefits of this treatment? Is it likely to help me live longer? Will it reduce or prevent symptoms?",
"       </li>",
"       <li>",
"        What are the downsides to this treatment?",
"       </li>",
"       <li>",
"        Are there other options besides this treatment?",
"       </li>",
"       <li>",
"        What happens if I do not have this treatment?",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H5325261\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/48/27394?source=see_link\">",
"       Patient information: Chondrosarcoma (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/3/31794?source=see_link\">",
"       Patient information: Ewing sarcoma (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/32/40450?source=see_link\">",
"       Patient information: Radiation therapy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/36/579?source=see_link\">",
"       Patient information: Managing pain when you have cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/4/29762?source=see_link\">",
"       Patient information: When your cancer treatment makes you tired (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/40/1667?source=see_link\">",
"       Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/57/19346?source=see_link\">",
"       Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/27/17842?source=see_link\">",
"       Patient information: Hair loss from cancer treatment (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/21/25939?source=see_link\">",
"       Patient information: Medical care during advanced illness (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?32/63/33778?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83150 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-02DD474397-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_63_33778=[""].join("\n");
var outline_f32_63_33778=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5325141\">",
"      What is bone cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5325156\">",
"      What are the symptoms of bone cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5325171\">",
"      Is there a test for bone cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5325186\">",
"      What is cancer staging?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5325201\">",
"      How is bone cancer treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5325216\">",
"      What happens after treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5325231\">",
"      What happens if my bone cancer comes back or spreads?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5325246\">",
"      What else should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5325261\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/48/27394?source=related_link\">",
"      Patient information: Chondrosarcoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/3/31794?source=related_link\">",
"      Patient information: Ewing sarcoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/27/17842?source=related_link\">",
"      Patient information: Hair loss from cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/40/1667?source=related_link\">",
"      Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/36/579?source=related_link\">",
"      Patient information: Managing pain when you have cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?25/21/25939?source=related_link\">",
"      Patient information: Medical care during advanced illness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/57/19346?source=related_link\">",
"      Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/32/40450?source=related_link\">",
"      Patient information: Radiation therapy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/4/29762?source=related_link\">",
"      Patient information: When your cancer treatment makes you tired (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_63_33779="Bacitracin: Pediatric drug information";
var content_f32_63_33779=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bacitracin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?6/20/6469?source=see_link\">",
"    see \"Bacitracin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/56/1925?source=see_link\">",
"    see \"Bacitracin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F138673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Baciguent&reg; [OTC];",
"     </li>",
"     <li>",
"      BACiiM&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F138674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Baciguent&reg;;",
"     </li>",
"     <li>",
"      Baciject&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1045467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Miscellaneous",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1045460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?6/20/6469?source=see_link\">",
"      see \"Bacitracin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M. (not recommended):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &le;2.5 kg: 900 units/kg/day in 2-3 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;2.5 kg: 1000 units/kg/day in 2-3 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 800-1200 units/kg/day divided every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 10,000-25,000 units/dose every 6 hours; not to exceed 100,000 units/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Topical: Apply 1-5 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Irrigation, solution: 50-100 units/mL in NS, LR, or sterile water for irrigation; soak sponges in solution for topical compresses 1-5 times/day or as needed during surgical procedures",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Antibiotic-associated colitis: Adults: Oral: 25,000 units every 6 hours for 7-10 days",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F138653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 50,000 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     BACiiM&trade;: 50,000 units",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, ophthalmic: 500 units/g (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical, as zinc [strength expressed as base]: 500 units/g (0.9 g, 15 g, 30 g, 120 g, 454 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Baciguent&reg;: 500 units/g (30 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F138638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1045470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: For I.M. administration, pH of urine should be kept above 6 by using sodium bicarbonate; bacitracin sterile powder should be dissolved in NS injection containing 2% procaine hydrochloride; administer I.M. injection into the upper outer quadrant of the buttocks; alternate injection sites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical: Apply thin layer to the cleansed affected area. May cover with a sterile bandage. For external use only. Do not use topical ointment in the eyes.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1045463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sterile powder should be stored in the refrigerator; once reconstituted, bacitracin is stable for 1 week under refrigeration (2&deg;C to 8&deg;C); incompatible with diluents containing parabens",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1045469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of pneumonia and empyema caused by susceptible staphylococci; prevention or treatment of superficial skin infections; due to its toxicity, use of bacitracin systemically or as an irrigant should be limited to situations where less toxic alternatives would not be effective; treatment of antibiotic-associated colitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F138702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Bacitracin may be confused with Bactrim&trade;, Bactroban&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F138700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest tightness, edema of face/lips, hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Itching, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, diarrhea, nausea, rectal itching, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Blood dyscrasias",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Nephrotoxicity (with systemic administration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1045473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bacitracin or any component; I.M. use is not recommended in patients with renal impairment",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1045459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prolonged use may result in overgrowth of nonsusceptible organisms",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1045458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.M. use may cause renal failure due to tubular and glomerular necrosis",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; avoid concurrent use with other nephrotoxic drugs; discontinue use if toxicity occurs; monitor renal function prior to therapy and daily during therapy",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; ensure adequate fluid intake and urinary output; should only be used where adequate laboratory facilities are available and when constant supervision is possible;  avoid concomitant use with other nephrotoxic drugs if possible; do not administer intravenously because severe thrombophlebitis occurs; bacitracin may be absorbed from denuded areas and irrigation sites",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F138647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6140224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is unknown if bacitracin crosses the placenta. The minimal absorption after topical use should limit the amount of medication available for transfer to the fetus. If ophthalmic agents are needed during pregnancy, the minimum effective dose should be used in combination with punctual occlusion to decrease potential exposure to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1045466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.M.: Urinalysis, renal function tests",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1045457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by preventing transfer of mucopeptides into the growing cell wall",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1045472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Poor from mucous membranes and intact skin; rapid following I.M. administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Minimally bound to plasma proteins",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: I.M.: Within 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Slow elimination into the urine with 10% to 40% of a dose excreted within 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1045465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/56/1925?source=see_link\">",
"      see \"Bacitracin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical bacitracin should not be used for longer than 1 week unless directed by a physician",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Kelly CP, Pothoulakis C, and LaMont JT, &ldquo;",
"      <i>",
"       Clostridium difficile",
"      </i>",
"      Colitis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1994, 330(4):257-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/63/33779/abstract-text/8043060/pubmed\" id=\"8043060\" target=\"_blank\">",
"        8043060",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12964 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.80.101-F119FB24C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_63_33779=[""].join("\n");
var outline_f32_63_33779=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708645\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138673\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138674\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045467\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045460\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138653\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138638\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045470\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045463\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045469\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138702\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138700\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045473\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045459\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045458\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298807\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138647\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6140224\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045466\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045457\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045472\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045465\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12964\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12964|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?6/20/6469?source=related_link\">",
"      Bacitracin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/56/1925?source=related_link\">",
"      Bacitracin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_63_33780="Lg cell ca lung histo";
var content_f32_63_33780=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F60987&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F60987&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Large cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large cell carcinoma histology. These are tumor cells with abundant cytoplasm and pleomorphic nuclei, but no evidence of either glandular differentiation, squamous differentiation, or evidence of mucin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Henry D. Tazelaar MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_63_33780=[""].join("\n");
var outline_f32_63_33780=null;
var title_f32_63_33781="Cystoscope components";
var content_f32_63_33781=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F83017&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F83017&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Cystoscope components",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 525px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) The parts of a basic cystoscope: 1) lens; 2) bridge; 3) sheath.",
"    <br>",
"     (B) Assembly of cystoscope parts.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_63_33781=[""].join("\n");
var outline_f32_63_33781=null;
var title_f32_63_33782="Radical inguinal orchiectomy for testicular germ cell tumors";
var content_f32_63_33782=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Radical inguinal orchiectomy for testicular germ cell tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/63/33782/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/63/33782/contributors\">",
"     Graeme S Steele, MBBCh, FCS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/63/33782/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/63/33782/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/63/33782/contributors\">",
"     Philip W Kantoff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/63/33782/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/63/33782/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/63/33782/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testicular cancers, 95 percent of which are germ cell tumors, have become one of the most curable solid neoplasms because of remarkable treatment advances that began in the late 1970s. Prior to that time, testicular cancer accounted for 11 percent of all cancer deaths in men between the ages of 25 to 34, and the five-year survival rate was 64 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33782/abstract/1\">",
"     1",
"    </a>",
"    ]. Now, the five-year survival rate is over 95 percent for both seminoma and nonseminomatous germ cell tumors (NSGCTs) (",
"    <a class=\"graphic graphic_table graphicRef81626 \" href=\"mobipreview.htm?43/42/44715\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33782/abstract/2\">",
"     2",
"    </a>",
"    ], and testicular cancer is responsible for about 350 deaths annually in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33782/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These improvements in outcome are related to a better understanding of the natural history of testicular tumors, improved staging and surgical techniques, the use of tumor markers to guide patient management, and the introduction of effective platinum-based combination chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33782/abstract/1,4,5\">",
"     1,4,5",
"    </a>",
"    ]. The consistently high cure rates in early stage disease have resulted in a shift in focus toward reducing treatment-related effects on reproductive function, as well as the toxicities associated with chemotherapy and radiation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/49/20250?source=see_link\">",
"     \"Treatment-related toxicity in men with testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radical orchiectomy for the diagnosis and treatment of men with suspected testicular cancer is discussed here. An overview of the management of testicular cancer is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13432?source=see_link\">",
"     \"Overview of the treatment of testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SURGICAL TREATMENT OF THE TESTIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to proceed with operative intervention in a man with a suspected testicular cancer is made after careful consideration of all available data, including the clinical findings, imaging studies, and serum tumor markers. Although frequently used to support a clinical suspicion of testicular cancer, scrotal ultrasound of a testicular mass cannot replace surgical and histologic examination of the testis based upon radical inguinal orchiectomy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/47/41720?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Radical inguinal orchiectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radical inguinal orchiectomy with high ligation of the spermatic cord at the level of internal ring is the procedure of choice for suspected testicular cancer.",
"   </p>",
"   <p>",
"    There are two main benefits from this procedure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Removal of the testis establishes the histopathologic tumor type and T stage, both of which have an important effect on subsequent management.",
"     </li>",
"     <li>",
"      Radical inguinal orchiectomy provides definitive local tumor control and causes minimal morbidity. Rare exceptions to this rule occur in patients who have tumor spillage at the time of radical orchiectomy, a partial or incomplete orchiectomy, or who undergo surgery with an inappropriate incision (eg, transscrotal surgery or transcrotal biopsy). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Scrotal violation'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radical inguinal orchiectomy can be performed under general, spinal, or local anesthesia, usually on an outpatient basis. The patient is placed in the supine position and the lower abdomen and scrotum are prepped and draped in routine fashion. An oblique incision is made in the inguinal area parallel to the inguinal canal, beginning just lateral to the pubic tubercle for a distance of approximately 5 cm. Larger tumors may require a slightly larger incision, which is extended toward the neck of the scrotum.",
"   </p>",
"   <p>",
"    The fascial layers of Camper and Scarpa are divided to the level of the external aponeurosis, which is then incised in the direction of its fibers to the level of the internal ring. The ilioinguinal nerve is identified, dissected free of the cord, and preserved. The spermatic cord is isolated and occluded at the level of the internal ring. The testis and its investing tunics are then delivered into the surgical field. Finally, the gubernacular attachments are divided, usually after they have been separated into two pedicles (vas deferens and spermatic vessels), and the spermatic cord is suture-ligated 1 to 2 cm inside the internal ring. The cord vessels are secured with silk ligatures, which can then be used to identify the spermatic cord stump if retroperitoneal lymphadenectomy is subsequently performed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/3/9272?source=see_link\">",
"     \"Retroperitoneal lymph node dissection in testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A saline-filled testicular prosthesis may be inserted at the time of radical inguinal orchiectomy. We and others have been impressed by the excellent cosmetic results and patient satisfaction with this procedure, although this option is largely based upon patient preference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33782/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. As an example, 86 patients who received a testicular prosthesis at surgery were evaluated at a median of six years after surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33782/abstract/8\">",
"     8",
"    </a>",
"    ]. The overall satisfaction with the surgical outcome was rated as excellent in 28 percent and good in 45 percent. Nine men (10 percent) regretted having the prosthesis placed and two subsequently had the prosthesis removed.",
"   </p>",
"   <p>",
"    If a diagnostic biopsy or subtotal orchiectomy is planned, it should be undertaken after the testis is mobilized via the above described suprainguinal incision. Isolation of the rest of the surgical field from the testis is mandatory prior to incision into testicular parenchyma to avoid scrotal violation. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Scrotal violation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The wound and scrotum are thoroughly irrigated and hemostasis is secured. Surgical closure is usually performed in layers followed by subcuticular skin closure and application of a compression dressing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common complication of radical orchiectomy is postoperative wound hemorrhage, which may cause either a scrotal or retroperitoneal hematoma. Complications related to radical inguinal orchiectomy only rarely necessitate a delay in the initiation of chemotherapy for men who require further therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/63/24568?source=see_link\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Delayed orchiectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For men who present with clinically advanced disease, we prefer to perform a radical orchiectomy prior to chemotherapy whenever possible. In our experience, chemotherapy does not impair wound healing following radical orchiectomy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/63/24568?source=see_link\">",
"     \"Initial risk-stratified treatment for advanced testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite this usual approach, there are some men who present with life-threatening advanced disease who undergo systemic chemotherapy prior to orchiectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33782/abstract/9-15\">",
"     9-15",
"    </a>",
"    ]. The rationale for late orchiectomy following chemotherapy is the presence of residual testicular disease in a significant percentage of patients, which cannot be distinguished by testicular ultrasound from the scar tissue that is present in almost all patients.",
"   </p>",
"   <p>",
"    The frequency of significant abnormalities in the orchiectomy specimen was illustrated in a series of 160 patients treated at Indiana University, in whom chemotherapy was given prior to surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33782/abstract/9\">",
"     9",
"    </a>",
"    ]. Residual carcinoma and pure teratoma were identified in 25 and 31 percent of cases, respectively, while necrosis or scar was present in the others.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Scrotal violation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suboptimal approaches to testicular neoplasms, such as scrotal orchiectomy, transscrotal biopsy, or fine-needle aspiration, are performed in 4 to 17 percent of patients. Some studies report a higher recurrence rate in patients with scrotal incisions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33782/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The need for additional therapy in men in whom scrotal violation has occurred is unclear.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series, there was no increase in the rate of local or distant recurrence in those receiving postorchiectomy chemotherapy among men who had scrotal orchiectomy compared to those undergoing and inguinal orchiectomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/63/33782/abstract/18\">",
"       18",
"      </a>",
"      ]. The overall disease-free survival rate was 99 percent. These early findings led to a recommendation for chemotherapy rather than surveillance strategies in men who had scrotal violation.",
"     </li>",
"     <li>",
"      Other series suggest that men who have scrotal violation may have a small increase in the incidence of local recurrence but this does not necessarily require further local or adjuvant systemic treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/63/33782/abstract/17,19,20\">",
"       17,19,20",
"      </a>",
"      ]. A meta-analysis compared 206 men with testicular cancer in whom scrotal violation had occurred at the time of orchiectomy to 976 cases undergoing conventional inguinal orchiectomy without scrotal violation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/63/33782/abstract/17\">",
"       17",
"      </a>",
"      ]. Although significant differences were noted in the local recurrence rate between the scrotal violation and inguinal orchiectomy groups, the overall local recurrence rates were small (2.9 versus 0.4 percent, respectively), and there were no significant differences in either distant recurrence or survival. Patients with scrotal violation who did not receive any local therapy (ie, radiation, scar excision) fared as well as those who did receive local therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest that scrotal violation does not impart a significantly worse overall prognosis and that scrotal violation in men with stage I disease (",
"    <a class=\"graphic graphic_table graphicRef81626 \" href=\"mobipreview.htm?43/42/44715\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef82117 \" href=\"mobipreview.htm?35/13/36061\">",
"     table 2",
"    </a>",
"    ) should not necessarily disqualify them from surveillance protocols.",
"   </p>",
"   <p>",
"    Although scrotal violation may not affect overall survival, we suggest the following in addition to spermatic cord excision, either before or after chemotherapy:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage I NSGCT &mdash; scrotal scar excision",
"     </li>",
"     <li>",
"      Stage I or II seminoma &mdash; extension of radiation portals to include the ipsilateral groin and scrotum if patients are to receive radiation therapy",
"     </li>",
"     <li>",
"      More advanced disease &mdash; We do not recommend additional local surgery in this subset of patients. These patients generally receive systemic therapy and local relapse following systemic treatment is rare.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Partial orchiectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Partial orchiectomy is sometimes used to preserve future fertility.",
"   </p>",
"   <p>",
"    A subset of carefully selected patients who have a solitary testicle, bilateral testicular tumors, or a strong suspicion of a benign lesion may be candidates for \"testis-sparing\" surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33782/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Bilateral simultaneous or sequential testicular germ cell tumors occur in 2 to 5 percent of affected men. Among those with second primary tumors, up to one-half present more than five years after the initial tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33782/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/25/2457?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology of and risk factors for testicular germ cell tumors\", section on 'Contralateral testicular cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A major concern when sparing part of a tumor-bearing testis is the high prevalence of adjacent foci of intratubular germ cell neoplasia (carcinoma in situ), which is present in as many as 85 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33782/abstract/27\">",
"     27",
"    </a>",
"    ]. Biopsy with frozen section analysis may be helpful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33782/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/27/42425?source=see_link\">",
"     \"Testicular intratubular germ cell neoplasia, unclassified (testicular carcinoma in situ, testicular intraepithelial neoplasia)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A report from the German Testicular Cancer Study Group described 73 men who underwent partial orchiectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33782/abstract/29\">",
"     29",
"    </a>",
"    ]. At a median follow-up of 91 months, only four had developed a local recurrence. All occurred in the setting of untreated intratubular germ cell neoplasia (carcinoma in situ) and all were successfully salvaged by inguinal orchiectomy. In 85 percent of these men normal serum testosterone concentrations were maintained.",
"   </p>",
"   <p>",
"    The optimal management of men who have undergone a partial orchiectomy is controversial. Some advocates of organ-preserving surgery in testicular cancer recommend that all patients be treated with adjuvant radiation therapy (18 to 20 Gy) to the retained testicular parenchyma because of risk of recurrence, regardless of whether the testicular tumor histology is seminoma or nonseminoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33782/abstract/22,29\">",
"     22,29",
"    </a>",
"    ]. However, such treatment invariably results in arrest of spermatogenesis and infertility, and has not become the standard of care. Others recommend it only when intratubular germ cell neoplasia is documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33782/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our view, partial orchiectomy should be considered only for carefully selected men with testicular cancer and a solitary testicle in whom preservation of fertility is an important consideration. Negative postresection biopsies of the tumor bed and absence of intratubular germ cell neoplasia in the remaining testicular parenchyma should be a sine qua non of this procedure, which should be carefully performed under conditions of cold ischemia to avoid tumor spillage or contamination. In addition, patient compliance for rigorous follow-up must be assured.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     FOLLOW-UP AFTER RADICAL ORCHIECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for further treatment following radical inguinal orchiectomy is dictated by the results of the staging evaluation, histologic type of malignancy, and postoperative serum tumor marker status. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13432?source=see_link\">",
"     \"Overview of the treatment of testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Serum tumor markers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated serum concentrations of tumor markers, particularly the beta subunit of human chorionic gonadotropin (beta-hCG) and alpha-fetoprotein (AFP), are common in patients with NSGCT and infrequently in those with pure seminoma. In men with stage I disease who have elevated serum tumor markers prior to radical orchiectomy, follow-up values should be obtained on a weekly basis to document the postorchiectomy decline. Rapid normalization of or a tenfold reduction in serum beta-hCG within two weeks and serum AFP within 25 to 30 days suggests elimination of the tumor, while persistent elevation of tumor markers after the period during which normalization is expected to occur may be the only evidence of persistent occult disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/58/38822?source=see_link\">",
"     \"Serum tumor markers in testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following successful initial treatment, periodic surveillance of serum beta-hCG and AFP is the most sensitive means of detecting early relapse. Recommended schedules for monitoring tumor markers and other follow-up studies are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/45/9943?source=see_link\">",
"     \"Posttreatment follow-up for men with testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/4/24645?source=see_link\">",
"       \"Patient information: Testicular cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For men with a suspected primary testicular cancer, we recommend orchiectomy to establish the histologic diagnosis and to provide definitive treatment of the primary tumor (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The standard approach for orchiectomy is a radical inguinal orchiectomy. Such men should not undergo a lesser procedure involving a scrotal violation, because of the risk of local recurrence. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Radical inguinal orchiectomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Scrotal violation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Partial orchiectomy is an alternative for men with a solitary testicle in whom preservation of fertility is an important consideration. Other options to preserve fertility, such as sperm cryopreservation, should also be considered. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Partial orchiectomy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/47/41720?source=see_link&amp;anchor=H18#H18\">",
"       \"Clinical manifestations, diagnosis, and staging of testicular germ cell tumors\", section on 'Cryopreservation of sperm'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Following orchiectomy, serum tumor markers should be monitored closely to ensure that orchiectomy removed all disease and to provide early evidence of any recurrence. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Serum tumor markers'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/45/9943?source=see_link\">",
"       \"Posttreatment follow-up for men with testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33782/abstract/1\">",
"      Einhorn LH. Treatment of testicular cancer: a new and improved model. J Clin Oncol 1990; 8:1777.",
"     </a>",
"    </li>",
"    <li>",
"     Ries LA, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1975-2001, National Cancer Institute, Bethesda, MD, 2004 file://seer.cancer.gov/csr/1975_2007/index.html (Accessed on April 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33782/abstract/3\">",
"      Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33782/abstract/4\">",
"      Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med 1997; 337:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33782/abstract/5\">",
"      Levin HS. Prognostic features of primary and metastatic testis germ-cell tumors. Urol Clin North Am 1993; 20:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33782/abstract/6\">",
"      Adshead J, Khoubehi B, Wood J, Rustin G. Testicular implants and patient satisfaction: a questionnaire-based study of men after orchidectomy for testicular cancer. BJU Int 2001; 88:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33782/abstract/7\">",
"      Turek PJ, Master VA, Testicular Prosthesis Study Group. Safety and effectiveness of a new saline filled testicular prosthesis. J Urol 2004; 172:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33782/abstract/8\">",
"      Yossepowitch O, Aviv D, Wainchwaig L, Baniel J. Testicular prostheses for testis cancer survivors: patient perspectives and predictors of long-term satisfaction. J Urol 2011; 186:2249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33782/abstract/9\">",
"      Leibovitch I, Little JS Jr, Foster RS, et al. Delayed orchiectomy after chemotherapy for metastatic nonseminomatous germ cell tumors. J Urol 1996; 155:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33782/abstract/10\">",
"      Simmonds PD, Mead GM, Lee AH, et al. Orchiectomy after chemotherapy in patients with metastatic testicular cancer. Is it indicated? Cancer 1995; 75:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33782/abstract/11\">",
"      Greist A, Einhorn LH, Williams SD, et al. Pathologic findings at orchiectomy following chemotherapy for disseminated testicular cancer. J Clin Oncol 1984; 2:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33782/abstract/12\">",
"      Ondrus D, Horn&aacute;k M, Breza J, et al. Delayed orchiectomy after chemotherapy in patients with advanced testicular cancer. Int Urol Nephrol 2001; 32:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33782/abstract/13\">",
"      Ramani VA, Grey BR, Addla SK, et al. Histological outcome of delayed orchidectomy after primary chemotherapy for metastatic germ cell tumour of the testis. Clin Oncol (R Coll Radiol) 2008; 20:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33782/abstract/14\">",
"      Geldart TR, Simmonds PD, Mead GM. Orchidectomy after chemotherapy for patients with metastatic testicular germ cell cancer. BJU Int 2002; 90:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33782/abstract/15\">",
"      Chong C, Logothetis CJ, von Eschenbach A, et al. Orchiectomy in advanced germ cell cancer following intensive chemotherapy: a comparison of systemic to testicular response. J Urol 1986; 136:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33782/abstract/16\">",
"      Giguere JK, Stablein DM, Spaulding JT, et al. The clinical significance of unconventional orchiectomy approaches in testicular cancer: a report from the Testicular Cancer Intergroup Study. J Urol 1988; 139:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33782/abstract/17\">",
"      Capelouto CC, Clark PE, Ransil BJ, Loughlin KR. A review of scrotal violation in testicular cancer: is adjuvant local therapy necessary? J Urol 1995; 153:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33782/abstract/18\">",
"      Pizzocaro G, Zanoni F, Salvioni R, et al. Difficulties of a surveillance study omitting retroperitoneal lymphadenectomy in clinical stage I nonseminomatous germ cell tumors of the testis. J Urol 1987; 138:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33782/abstract/19\">",
"      Kennedy CL, Hendry WF, Peckham MJ. The significance of scrotal interference in stage I testicular cancer managed by orchiectomy and surveillance. Br J Urol 1986; 58:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33782/abstract/20\">",
"      Thomas GM, Sturgeon JF, Alison R, et al. A study of post-orchiectomy surveillance in stage I testicular seminoma. J Urol 1989; 142:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33782/abstract/21\">",
"      Heidenreich A, H&ouml;ltl W, Albrecht W, et al. Testis-preserving surgery in bilateral testicular germ cell tumours. Br J Urol 1997; 79:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33782/abstract/22\">",
"      Yossepowitch O, Baniel J. Role of organ-sparing surgery in germ cell tumors of the testis. Urology 2004; 63:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33782/abstract/23\">",
"      Schmoll HJ, Souchon R, Krege S, et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004; 15:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33782/abstract/24\">",
"      Sonneveld DJ, Schraffordt Koops H, Sleijfer DT, Hoekstra HJ. Bilateral testicular germ cell tumours in patients with initial stage I disease: prevalence and prognosis--a single centre's 30 years' experience. Eur J Cancer 1998; 34:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33782/abstract/25\">",
"      Holzbeierlein JM, Sogani PC, Sheinfeld J. Histology and clinical outcomes in patients with bilateral testicular germ cell tumors: the Memorial Sloan Kettering Cancer Center experience 1950 to 2001. J Urol 2003; 169:2122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33782/abstract/26\">",
"      Che M, Tamboli P, Ro JY, et al. Bilateral testicular germ cell tumors: twenty-year experience at M. D. Anderson Cancer Center. Cancer 2002; 95:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33782/abstract/27\">",
"      Dieckmann KP, Skakkebaek NE. Carcinoma in situ of the testis: review of biological and clinical features. Int J Cancer 1999; 83:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33782/abstract/28\">",
"      Connolly SS, D'Arcy FT, Bredin HC, et al. Value of frozen section analysis with suspected testicular malignancy. Urology 2006; 67:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33782/abstract/29\">",
"      Heidenreich A, Weissbach L, H&ouml;ltl W, et al. Organ sparing surgery for malignant germ cell tumor of the testis. J Urol 2001; 166:2161.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2986 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.123.134.1-8BED796ECD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_63_33782=[""].join("\n");
var outline_f32_63_33782=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SURGICAL TREATMENT OF THE TESTIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Radical inguinal orchiectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Delayed orchiectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Scrotal violation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Partial orchiectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      FOLLOW-UP AFTER RADICAL ORCHIECTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Serum tumor markers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2986\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2986|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/42/44715\" title=\"table 1\">",
"      Testicular tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/13/36061\" title=\"table 2\">",
"      TNM staging testicular CA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/47/41720?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/25/2457?source=related_link\">",
"      Epidemiology of and risk factors for testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/63/24568?source=related_link\">",
"      Initial risk-stratified treatment for advanced testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13432?source=related_link\">",
"      Overview of the treatment of testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/4/24645?source=related_link\">",
"      Patient information: Testicular cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/45/9943?source=related_link\">",
"      Posttreatment follow-up for men with testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/3/9272?source=related_link\">",
"      Retroperitoneal lymph node dissection in testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/58/38822?source=related_link\">",
"      Serum tumor markers in testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/27/42425?source=related_link\">",
"      Testicular intratubular germ cell neoplasia, unclassified (testicular carcinoma in situ, testicular intraepithelial neoplasia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/49/20250?source=related_link\">",
"      Treatment-related toxicity in men with testicular germ cell tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_63_33783="ECG sick sinus syndrome";
var content_f32_63_33783=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51193&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51193&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1137px;\">",
"  <div class=\"figure\" style=\"width: 567px\">",
"   <div class=\"ttl\">",
"    Single lead electrocardiogram (ECG) showing sick sinus syndrome and atrial fibrillation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 547px; height: 113px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Rhythm strip showing sick sinus syndrome. The initial part (left) of the tracing reveals coarse atrial fibrillation with irregular ventricular response in the absence of drugs that slow AV nodal conduction. The atrial fibrillation terminates and is followed by a sinus beat with a prolonged sinus node recovery time of nearly four seconds.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_63_33783=[""].join("\n");
var outline_f32_63_33783=null;
var title_f32_63_33784="Mechanisms of solute clearance and ultrafiltration in peritoneal dialysis";
var content_f32_63_33784=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mechanisms of solute clearance and ultrafiltration in peritoneal dialysis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/63/33784/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/63/33784/contributors\">",
"     Madhukar Misra, MD, FRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/63/33784/contributors\">",
"     Ramesh Khanna, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/63/33784/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/63/33784/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/63/33784/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/63/33784/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/63/33784/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic peritoneal dialysis (as with CAPD) can be complicated by problems with either solute clearance (which occurs by solute diffusion from the plasma into dialysate) or ultrafiltration (which is driven by the osmotic gradient between the hyperosmotic dialysate and the plasma). The mechanisms of solute clearance and ultrafiltration across the peritoneal membrane will be reviewed here. The clinical issues that can arise are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23337?source=see_link\">",
"     \"Problems with solute clearance and ultrafiltration in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES OF TRANSPORT ACROSS THE PERITONEAL MEMBRANE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The average surface area of the peritoneal membrane is between 1.0 and 1.3 m2 in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. During peritoneal dialysis, it is principally the parietal peritoneum that participates in peritoneal transport, since only about one-third of the visceral peritoneum is in contact with the dialysis solution at a given time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition to the capillary surface area, the diffusion length between the dialysate and the mesothelium also plays an important role in the overall transport characteristics of the peritoneum.",
"   </p>",
"   <p>",
"    There are three barriers between the dialysate in the peritoneum and capillary blood: the capillary wall, which is most important; the interstitium; and the mesothelial cell layer. The mesothelial cell layer does not constitute a major barrier to solute or water transport across the peritoneum, while the interstitium offers some resistance to solute transport that is mainly restricted to large solutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pores for solute transport",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to the three-pore model of solute transport, the capillary wall consists of a system of pores of three sizes, which are size-selective in restricting solute transport [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is an abundance of small pores (average radius 40 to 50 &Aring;) that mediate the transport of lower molecular weight solutes. The transport of these solutes is limited by the number of small pores.",
"     </li>",
"     <li>",
"      The large pores constitute less than 0.1 percent of the total number of pores but are much larger than the small pores (average radius &gt;150 &Aring;). The radii of the smaller pores are constant, while the larger pores vary in size.",
"     </li>",
"     <li>",
"      Ultrasmall pores (3 to 5 &Aring;), which constitute the third pore, are discussed in the next section.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Aquaporin-1 and water transport",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peritoneal membrane contains ultrasmall pore water channels (3 to 5 &Aring;), called aquaporin-1, which constitute the third pore in three pore models of solute transport [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/5,7-10\">",
"     5,7-10",
"    </a>",
"    ]. This is the same water channel present in red blood cells and the proximal tubule in the kidney [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/11\">",
"     11",
"    </a>",
"    ], but different from aquaporin-2, which is the antidiuretic hormone-sensitive water channel in the collecting tubule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/12\">",
"     12",
"    </a>",
"    ]. Aquaporin-1, which is permeable only to water, is present in the endothelial cells of the peritoneal microvasculature as the major water channel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Peritoneal tissue also contains small numbers of aquaporin-3 and aquaporin-4 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The aquaporin system is responsible for transcellular water transport induced by the osmotic gradient created by adding hypertonic dialysate to the peritoneum. On average, it accounts for approximately 40 percent of total capillary ultrafiltration, with the remainder occurring via the paracellular route between the cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/5,14\">",
"     5,14",
"    </a>",
"    ]. As an example, cumulative ultrafiltration is reduced by approximately 50 to 60 percent in mice lacking the aquaporin-1 gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. By comparison, the absence of aquaporin-4 had no effect on osmotic water transport. Unlike aquaporin-mediated transport that is primarily determined by the osmotic gradient, the small pore water transport is dependent upon non-osmotic determinants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/17\">",
"     17",
"    </a>",
"    ]. Aquaporin-1 may also be involved in vascular proliferation and leucocyte recruitment during inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Solute transport",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solute transport across the peritoneum occurs via diffusion down a favorable concentration gradient (eg, high blood urea concentration compared to none in the dialysate) or convection.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diffusion varies directly with the magnitude of the concentration gradient and inversely with the size of the solute.",
"     </li>",
"     <li>",
"      Convection or solvent drag refers to solute transport that occurs with ultrafiltration (ie, water transport induced by an osmotic gradient), a process that is mediated by the frictional forces between water and solute. For any given solute, convection is measured by the sieving coefficient (S). S represents the ratio between the concentration of the solute in the ultrafiltrate and its concentration in the plasma, assuming that net diffusion is zero. On the other hand, the osmotic effectiveness of a solute against a membrane is measured by the reflection coefficient. The reflection coefficient (rc) varies from zero if the membrane offers no resistance to transport of the solute to one for an ideal semipermeable membrane that is completely impermeable to the solute. The relationship between these two parameters for an isoporous membrane is given by the equation: S &nbsp;= &nbsp;(1 &nbsp;- &nbsp;rc).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Low molecular weight solutes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transport of low molecular weight solutes (eg, urea and creatinine) across the peritoneum primarily occurs by diffusion. This process is size-selective (small solutes diffusing at a faster rates than the larger solutes) and the rate is dependent upon the concentration gradient, peritoneal surface area, and peritoneal permeability. Peritoneal transport, at least in theory, may also be affected by other factors such as vascular supply and the peritoneal charge. However, their overall contribution to solute transport is minimal at best.",
"   </p>",
"   <p>",
"    The size-selectivity of the peritoneal membrane is often expressed by the term restriction coefficient, in which a value of 1.0 implies absence of a size restriction barrier. Thus, the higher the value of the restriction coefficient, the lower the size-selective permeability of the peritoneum.",
"   </p>",
"   <p>",
"    The concept of mass transfer area coefficient (MTAC) represents the theoretical maximal peritoneal clearance by diffusion at time zero, ie, before any solute transport has occurred. At this time, the concentration gradient across the membrane is at its highest and then progressively falls as solute diffuses from a compartment of high concentration to one of low concentration. In one of the simpler equations, small solute transfer is supposed to follow first order kinetics with the contribution of convection assumed to be negligible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;In [(P - D0) &nbsp;&divide; &nbsp;(P - Dt)]",
"    <br/>",
"    &nbsp;MTAC &nbsp;= &nbsp;",
"    <span class=\"nowrap\">",
"     (Vt/t)",
"    </span>",
"   </p>",
"   <p>",
"    where Vt is the drained dialysate volume, t is the time, D0 and Dt are dialysate solute concentrations at start and at time t, and P is the plasma solute concentration.",
"   </p>",
"   <p>",
"    Modifications of this equation that correct for convection have been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The calculation of MTAC, which is a research tool, is usually performed after a four to six hour dwell since inaccurate values may be obtained during shorter dwell times due to a large convective component and other factors. The relationship between the more commonly used",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    ratios (after a four-hour dwell) (",
"    <a class=\"graphic graphic_figure graphicRef75224 \" href=\"mobipreview.htm?32/26/33198\">",
"     figure 1",
"    </a>",
"    ) and MTAC is generally linear. However,",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    values may overestimate or underestimate MTAC when the MTAC is very low or very high, respectively.",
"   </p>",
"   <p>",
"    Transport across the peritoneal membrane also occurs in the opposite direction, from the peritoneal cavity to the vascular compartment, via a process that is mainly diffusive and therefore size-selective. This is particularly true of osmotic agents used in dialysis solutions such as glucose, glycerol, and amino acids. As an example, approximately 66 percent of the total instilled quantity of glucose is absorbed independent of the dialysate concentration used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/22\">",
"     22",
"    </a>",
"    ]. For solutes with a higher molecular weight, this transport occurs via a combination of convection (predominantly through lymphatics) and transport to the peritoneal interstitium, via transmesothelial route. (See fluid transport below). The relative proportion of convection to diffusion is 0.1 for a small molecule like glucose compared to 10 for a large molecule like Hb when administered intraperitoneally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is appreciable variation in the rate of solute transport among individuals, as some are slow transporters and approximately 15 percent are rapid transporters. It is now well appreciated that peritoneal dialysis (PD) patients have different peritoneal membrane transport characteristics. These differences are best classified and determined by use of the peritoneal equilibration test (",
"    <a class=\"graphic graphic_figure graphicRef62604 \" href=\"mobipreview.htm?6/26/6574\">",
"     figure 2",
"    </a>",
"    ). Rapid transporters reach urea and creatinine equilibration more quickly and the dialysate volume falls after two hours due to continuous backabsorption of fluid from the peritoneal cavity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/31/5623?source=see_link\">",
"     \"Peritoneal equilibration test\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rate of low molecular weight solutes also varies with dialysate instilled volume, with increased clearance being observed with increased volume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/25\">",
"     25",
"    </a>",
"    ]. By comparison, the clearance of beta 2 microglobulin, a middle sized molecule, does not appear to change with changing instilled volume.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     High molecular weight solutes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peritoneal transport of larger molecules occurs at a much slower rate. Thus, creatinine (mol wt 113) is slower than urea (mol wt 56), inulin (mol wt 5200) is slower than creatinine, and larger proteins cross the peritoneum very slowly (",
"    <a class=\"graphic graphic_figure graphicRef75224 \" href=\"mobipreview.htm?32/26/33198\">",
"     figure 1",
"    </a>",
"    ). Proteins with higher molecular weights such as albumin, transferrin and IgG utilize the large pores described above for transport across the peritoneal membrane. The exact mode of this process is a subject of debate but both size-selective diffusion and convection appear to contribute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/26\">",
"     26",
"    </a>",
"    ]. Regardless of the mechanism, this process is sufficiently slow that serum proteins are present in low concentration in the dialysate and equilibration with the plasma does not occur at clinically used dwell times. As a result, the clearance of these molecules approximates their MTAC.",
"   </p>",
"   <p>",
"    Both peritoneal permeability and the surface area of the peritoneal membrane influence the transfer of these larger solutes. The transport of these solutes out of the peritoneal cavity primarily occurs via the subdiaphragmatic lymphatics and, to a lesser degree, the peritoneal interstitium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/23,27\">",
"     23,27",
"    </a>",
"    ]. This process is independent of molecular size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Electrolytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transport of electrolytes, such as sodium, potassium. and bicarbonate, across the peritoneal membrane may have important therapeutic implications. The dialysate concentration of sodium shows a decline in the initial phase of a hypertonic dwell followed by a gradual increase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. The initial stage in this phenomenon, which is known as sodium sieving, results from selective transcellular water transport through ultrasmall, water-selective aquaporin-1 pores, lowering the dialysate sodium concentration by dilution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/30\">",
"     30",
"    </a>",
"    ]. Thus, short exchanges with hypertonic dialysate can lead to hypernatremia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The gradual rise in the dialysate sodium concentration in the latter phase of the dwell is due to diffusion of sodium from the circulation. The MTAC for sodium is 4",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    when hypertonic glucose (3.86 percent) is used as a dialysate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/32\">",
"     32",
"    </a>",
"    ], while values of 9",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    have been reported for chloride [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/33\">",
"     33",
"    </a>",
"    ]. Despite having a lower molecular weight than urea (23 versus 60), the MTAC of sodium is significantly lower. Thus, sodium behaves as a larger molecule, probably due to hydration-induced alterations in its configuration. By comparison, the MTACs for urea and creatinine are approximately 16.0 and &nbsp;9.4",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m2, respectively.",
"   </p>",
"   <p>",
"    The average MTAC for the clearance of potassium by diffusion is between 12 and 16",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    in patients on continuous ambulatory peritoneal dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Potassium may be also be released from the peritoneal lining, resulting in MTAC values as high as 24",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    during the first hour.",
"   </p>",
"   <p>",
"    Because of favorable concentration gradients, there is a net mass transfer of calcium and magnesium from the dialysate to the vascular compartment by diffusion. The standard dialysate concentrations of calcium and magnesium are 1.75 and 0.75",
"    <span class=\"nowrap\">",
"     mmol/L,",
"    </span>",
"    which are higher than the free (ie, unbound) concentrations in the plasma (1.25 and 0.55",
"    <span class=\"nowrap\">",
"     mmol/L,",
"    </span>",
"    respectively). When higher glucose concentrations are used, this net transfer is balanced by convective transport due to ultrafiltration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The MTAC for bicarbonate (mol wt 61) is approximately 9.5",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/36\">",
"     36",
"    </a>",
"    ]. Bicarbonate loss in peritoneal dialysis is dependent upon the plasma bicarbonate concentration (with lower values minimizing diffusion from plasma into the dialysate) and convective loss secondary to ultrafiltration. Standard dialysate contains lactate as a source of buffer at a concentration of 35",
"    <span class=\"nowrap\">",
"     mmol/L.",
"    </span>",
"    The use of standard dialysate results in an initial net diffusive and convective bicarbonate loss into the dialysate; this is counterbalanced by the movement of dialysate lactate into the blood, as the subsequent metabolism of lactate generates bicarbonate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The acid-base status of a patient on peritoneal dialysis is determined by the relationship between total metabolic acid production (a function of protein breakdown) and net loss or gain of base (bicarbonate loss versus lactate gain). An increase in the dose of dialysis (ie, increased number of exchanges) results in a net gain of lactate that can cause metabolic alkalosis. This phenomenon reflects maximum transfer of lactate during the initial part of the dwell when the dialysate lactate concentration is at its highest.",
"   </p>",
"   <p>",
"    Similar principles apply to the acid-base status of patients using bicarbonate-based peritoneal dialysis solutions. In this setting, bicarbonate diffusion out of the dialysate is partially counterbalanced by convective bicarbonate loss into the dialysate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Fluid transport",
"    </span>",
"    &nbsp;&mdash;&nbsp;Net transcapillary ultrafiltration (TCUF) is determined by the difference between the cumulative fluid transfer into the peritoneal cavity by ultrafiltration and the uptake of fluid out of the peritoneum predominantly through peritoneal lymphatics. Transcapillary ultrafiltration of water occurs via the small pores in the peritoneal membrane and the ultrasmall transcellular water channels (aquaporin-1). As mentioned above, the ultrasmall pores contribute as much as 40 percent to the total filtered volume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The TCUF rate is determined by the net difference of osmotic and hydraulic pressures and the ultrafiltration coefficient of the peritoneal membrane and is governed by Starling's law. Thus the TCUF rate is equal to:",
"   </p>",
"   <p>",
"    &nbsp;UFC &nbsp; x &nbsp;",
"    <span class=\"nowrap\">",
"     (&Delta;",
"    </span>",
"    hydraulic pressure &nbsp; - &nbsp;",
"    <span class=\"nowrap\">",
"     &Delta;",
"    </span>",
"    osmotic pressure)",
"   </p>",
"   <p>",
"    which can be expressed as:",
"   </p>",
"   <p>",
"    &nbsp;UFC &nbsp; x &nbsp; [(Pcap &nbsp;- &nbsp; Pperit) &nbsp; - &nbsp;",
"    <span class=\"nowrap\">",
"     (&Delta;&pi;",
"    </span>",
"    &nbsp;+ &nbsp;",
"    <span class=\"nowrap\">",
"     s&Delta;O)]",
"    </span>",
"   </p>",
"   <p>",
"    Where UFC is peritoneal ultrafiltration coefficient, which is determined by the peritoneal surface area and its hydraulic permeability,",
"    <span class=\"nowrap\">",
"     &Delta;&pi;",
"    </span>",
"    is the oncotic or colloid osmotic pressure gradient, s is the reflection coefficient,",
"    <span class=\"nowrap\">",
"     &Delta;O",
"    </span>",
"    is the crystalloid osmotic pressure gradient (primarily determined by glucose), and cap and perit refers to values in the capillary and peritoneal fluid, respectively.",
"   </p>",
"   <p>",
"    The intraperitoneal pressure (Pperit) is the major determinant of the hydraulic pressure gradient across the peritoneal membrane. The intraperitoneal pressure is directly dependent upon the instilled dialysate volume [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/37\">",
"     37",
"    </a>",
"    ]. It is also influenced by posture, being approximately 2 to 8 mmHg when supine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/38,39\">",
"     38,39",
"    </a>",
"    ], but as high as 20 mmHg in the upright position eg, walking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/38\">",
"     38",
"    </a>",
"    ]. In one study, for example, a 10 mmHg elevation in intraperitoneal pressure reduced net ultrafiltration by 1.1",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    due both to reduced transcapillary ultrafiltration and increased lymphatic absorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The peritoneal capillary colloid osmotic pressure in peritoneal dialysis patients is approximately 21 mmHg [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/40\">",
"     40",
"    </a>",
"    ]. Dialysate glucose is the major determinant of the crystalloid component of osmotic pressure. During CAPD, mean values for the osmotic reflection coefficient of glucose are reported as being quite low (approximately 0.02 to 0.05) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/33,41-44\">",
"     33,41-44",
"    </a>",
"    ]. This value is dependent upon the pore size in the peritoneal membrane. The reflection coefficient for glucose is 1 (ie, no transport) across the ultrasmall pores but approaches zero (ie, unrestricted transport) across the large pores.",
"   </p>",
"   <p>",
"    The small solute component of the osmotic pressure gradient is maximal at the start of the dwell and dissipates with time as the dialysate glucose concentration falls due to both absorption into the systemic circulation and dilution by ultrafiltration; the net effect is that the maximum TCUF occurs at the start of the dwell [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/45\">",
"     45",
"    </a>",
"    ]. The mean TCUF for a four hour dwell with glucose varies with the glucose concentration being 1.0 to 1.2",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    for 1.36 percent glucose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/46,47\">",
"     46,47",
"    </a>",
"    ] and 3.4",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    for 3.86 percent glucose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The peritoneal membrane is relatively impermeable to large molecules, such as proteins and the glucose polymer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/36/44612?source=see_link\">",
"     icodextrin",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef75224 \" href=\"mobipreview.htm?32/26/33198\">",
"     figure 1",
"    </a>",
"    ). When such solutes are present in the dialysate, there is a net fluid flow into the dialysate, a process termed colloid osmosis that is similar to the effect of plasma proteins to keep fluid in the vascular space. Such solutions utilize the small pore system for fluid transport. The pressure gradient exerted by these solutions is higher than the commonly used 1.5 percent glucose-based dialysis solutions (even though they are isosmolar) but lower than 4.25 percent glucose-based solutions.",
"   </p>",
"   <p>",
"    The main advantage of using such colloid solutions is a slower loss of gradient dissipation compared to that due to the absorption of glucose. This property provides the rationale for the use of 7.5 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/36/44612?source=see_link\">",
"     icodextrin",
"    </a>",
"    solutions for inducing TCUF. The absorption of icodextrin is only about 20 percent during an eight-hour exchange; allowing ultrafiltration to be maintained over at least 12 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/40,47-49\">",
"     40,47-49",
"    </a>",
"    ]. The mean ultrafiltration rate obtained by such colloid osmosis is between 1.4 to 2.3",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/48,50\">",
"     48,50",
"    </a>",
"    ]. In a randomized controlled trial, isosmolar icodextrin (282",
"    <span class=\"nowrap\">",
"     mosmol/kg)",
"    </span>",
"    produced 3.5 times more ultrafiltration at eight hours and 5.5 times more at twelve hours than conventional 1.36 percent glucose dialysate (346",
"    <span class=\"nowrap\">",
"     mosmol/kg)",
"    </span>",
"    and was of equivalent efficacy to hypertonic 3.86 percent glucose (484",
"    <span class=\"nowrap\">",
"     mosmol/kg)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/48\">",
"     48",
"    </a>",
"    ]. Icodextrin has been approved by the Food and Drug Administration (FDA).",
"   </p>",
"   <p>",
"    At all times and with all solutions, TCUF is counterbalanced by peritoneal reabsorption. The main routes of reabsorption being via the lymphatics and backfiltration by colloid osmosis. The lymphatic absorption rate varies directly with the intraperitoneal pressure, being higher with higher pressures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL CORRELATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding discussion on solute clearance and ultrafiltration assumes significance when considering the common clinical problem of ultrafiltration failure. The frequency of this problem increases with time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23337?source=see_link\">",
"     \"Problems with solute clearance and ultrafiltration in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with ultrafiltration failure are typically evaluated with a peritoneal equilibration test. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/31/5623?source=see_link\">",
"     \"Peritoneal equilibration test\"",
"    </a>",
"    .) There are four major causes of ultrafiltration failure:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Large peritoneal vascular surface area, leading to significant glucose absorption",
"     </li>",
"     <li>",
"      Impaired aquaporin-1-mediated water transport",
"     </li>",
"     <li>",
"      Increased lymphatic absorption",
"     </li>",
"     <li>",
"      Peritoneal adhesions, leading to a small peritoneal vascular surface area",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Large or small peritoneal vascular surface area",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common type of ultrafiltration failure is associated with high dialysate-to-plasma ratios of small molecular weight solutes and is presumably due to an increase in peritoneal vascular surface area [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Although a higher water transport rate is achievable with a large surface area, the concomitant increase in absorption of glucose dissipates the osmotic gradient relatively early, resulting in loss of ultrafiltration (",
"    <a class=\"graphic graphic_figure graphicRef62604 \" href=\"mobipreview.htm?6/26/6574\">",
"     figure 2",
"    </a>",
"    ). There is no uniform agreement as to what causes high permeability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/53\">",
"     53",
"    </a>",
"    ]. Most believe it is due to larger surface area; however, there may be other causes that are not well defined, such as increased blood flow during an acute peritonitis.",
"   </p>",
"   <p>",
"    This abnormality is called type 1 membrane failure and these patients are called rapid transporters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/51\">",
"     51",
"    </a>",
"    ]. The frequency of this rapid transport increases over time (",
"    <a class=\"graphic graphic_figure graphicRef64191 \" href=\"mobipreview.htm?25/53/26461\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36215?source=see_link\">",
"     \"Rapid transporters on maintenance peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Compared with glucose based dialysate, the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/36/44612?source=see_link\">",
"     icodextrin",
"    </a>",
"    may be associated with greater preservation of peritoneal membrane function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Type 2 failure, on the other hand, is associated with reductions in both solute transport and ultrafiltration due to a small peritoneal vascular surface area. This disorder is rare, often occurring in conjunction with sclerosing encapsulating peritonitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23337?source=see_link\">",
"     \"Problems with solute clearance and ultrafiltration in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Impaired aquaporin-1-mediated water transport",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impairment in aquaporin-1 (ultrasmall pore) expression and, more often, function can contribute to ultrafiltration failure. Constant exposure to glucose may eventually lead to peritoneal neoangiogenesis (similar to retinal neoangiogenesis in diabetics) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/55\">",
"     55",
"    </a>",
"    ], leading to both increased peritoneal vascular surface area and transcellular glycosylation of aquaporin-1. The prevalence of impaired aquaporin-1-mediated water transport as a cause of ultrafiltration failure is not known but is probably very low.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Assessment of aquaporin-1 function",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, the dialysate concentration of sodium falls during the initial phase of a hypertonic dwell, followed by a gradual increase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. The initial fall in sodium concentration, which is known as sodium sieving, results from selective transcellular water transport through the water-selective aquaporin-1 pores, lowering the dialysate sodium concentration by dilution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/30\">",
"     30",
"    </a>",
"    ]. Thus, the extent of sodium sieving during a hypertonic exchange can provide an estimate of the overall function of these water channels and aquaporin-1 function (",
"    <a class=\"graphic graphic_figure graphicRef67695 \" href=\"mobipreview.htm?34/9/34974\">",
"     figure 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The net ultrafiltration obtained during the first two hours of an exchange with 4.25 percent glucose is compared to 1.5 percent glucose. This difference becomes smaller with impairment of aquaporin-1-mediated TCUF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several direct methods to assess free water transport have been described. These include quantification of free water transport from a single standard peritoneal function test and by using a 4.25 percent mini PET (one hour) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ultrafiltration in patients with impaired aquaporin-1 function occurs via non-channel-mediated pathways which, as mentioned above, are responsible for approximately 60 percent of water transport across the peritoneal membrane [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Ultrafiltration can be enhanced in this setting by using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/36/44612?source=see_link\">",
"     icodextrin",
"    </a>",
"    in long dwell exchanges. Alternatively, 4.25 percent glucose exchanges with short dwell times may be helpful to some extent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Increased lymphatic absorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;A decrease in net ultrafiltration due to enhanced lymphatic absorption (normally accounting for 10 to 20 percent of fluid reabsorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/58\">",
"     58",
"    </a>",
"    ]) can occur in association with a large peritoneal vascular surface area. In such a setting, all measures that are utilized to enhance ultrafiltration should be instituted, including short cycle times, high glucose concentrations, and use of supine dialysis (net ultrafiltration in the supine position is approximately 16 percent higher, due largely to a lower intraperitoneal pressure) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/59\">",
"     59",
"    </a>",
"    ]. Macromolecule, albumin or hemoglobin absorption from the peritoneal cavity is increased in patients with increased lymphatic absorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/45\">",
"     45",
"    </a>",
"    ]. Increased duration of peritoneal dialysis does not appear to enhance lymphatic absorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/63/33784/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10255146\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The peritoneal barrier is composed of three layers including the peritoneal mesothelium, interstitium and the capillary endothelium. According to the three-pore model of solute transport, the capillary endothelium contains three different-sized pores which are size-selective in restricting solute transport. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles of transport across the peritoneal membrane'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aquaporin-1 is the smallest sized pore and is responsible for almost 40 percent of free water transport across the peritoneal membrane. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Aquaporin-1 and water transport'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The transport of different solutes across the peritoneal membrane is based on diffusion and convection. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Solute transport'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The transcapillary ultrafiltration rate is determined by the net pressure gradient as well as by peritoneal membrane characteristics and is determined by Starling&rsquo;s law. Both crystalloids",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      colloid based dialysis solutions may be used to provide the required osmotic or oncotic gradients across the peritoneal membrane. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Fluid transport'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The rate of solute transport varies between individuals, which may have therapeutic implications for dialysis adequacy as well as fluid overload. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical correlates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ultrafiltration failure may be a result of alterations in the vascular surface area (larger vascular surface area makes more pores available for transport), which leads to the rapid dissipation of glucose gradient across the membrane and fluid retention. Selective loss of aquaporin-1 function and other factors can also lead to ultrafiltration failure. The cause of ultrafiltration failure can often be determined by conducting special studies on the peritoneal membrane. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical correlates'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/1\">",
"      Esperanca, MJ, Collins, DL. Peritoneal dialysis efficiency in relation to body weight. J Pediatr Surg 1966; 1:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/2\">",
"      Pawlaczyk K, Kuzlan M, Wieczorowska-Tobis K, et al. Species-dependent topography of the peritoneum. Adv Perit Dial 1996; 12:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/3\">",
"      Flessner MF. Small-solute transport across specific peritoneal tissue surfaces in the rat. J Am Soc Nephrol 1996; 7:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/4\">",
"      Fox JR, Wayland H. Interstitial diffusion of macromolecules in the rat mesentery. Microvasc Res 1979; 18:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/5\">",
"      Rippe B, Venturoli D, Simonsen O, de Arteaga J. Fluid and electrolyte transport across the peritoneal membrane during CAPD according to the three-pore model. Perit Dial Int 2004; 24:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/6\">",
"      Waniewski J, Debowska M, Lindholm B. How accurate is the description of transport kinetics in peritoneal dialysis according to different versions of the three-pore model? Perit Dial Int 2008; 28:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/7\">",
"      Rippe, B. A three pore model of peritoneal transport. Perit Dial Int 2000; 13(Suppl 2):S35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/8\">",
"      Pannekeet MM, Mulder JB, Weening JJ, et al. Demonstration of aquaporin-CHIP in peritoneal tissue of uremic and CAPD patients. Perit Dial Int 1996; 16 Suppl 1:S54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/9\">",
"      Rippe B, Carlsson O. Role of transcellular water channels in peritoneal dialysis. Perit Dial Int 1999; 19 Suppl 2:S95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/10\">",
"      Marples D. Aquaporins: roles in renal function and peritoneal dialysis. Perit Dial Int 2001; 21:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/11\">",
"      Lee MD, King LS, Agre P. The aquaporin family of water channel proteins in clinical medicine. Medicine (Baltimore) 1997; 76:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/12\">",
"      Nielsen S, Kwon TH, Christensen BM, et al. Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol 1999; 10:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/13\">",
"      Akiba T, Ota T, Fushimi K, et al. Water channel AQP1, 3, and 4 in the human peritoneum and peritoneal dialysate. Adv Perit Dial 1997; 13:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/14\">",
"      Rippe B, Stelin G. Simulations of peritoneal solute transport during CAPD. Application of two-pore formalism. Kidney Int 1989; 35:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/15\">",
"      Yang B, Folkesson HG, Yang J, et al. Reduced osmotic water permeability of the peritoneal barrier in aquaporin-1 knockout mice. Am J Physiol 1999; 276:C76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/16\">",
"      Ni J, Verbavatz JM, Rippe A, et al. Aquaporin-1 plays an essential role in water permeability and ultrafiltration during peritoneal dialysis. Kidney Int 2006; 69:1518.",
"     </a>",
"    </li>",
"    <li>",
"     Parikova, A, Smit, W, Zweers, MM. Free water transport, small pore transport and the osmotic pressure gradient. Nephrol Dial Transplant 2007 [Epub ahead of print].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/18\">",
"      Devuyst O, Yool AJ. Aquaporin-1: new developments and perspectives for peritoneal dialysis. Perit Dial Int 2010; 30:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/19\">",
"      Henderson LW, Nolph KD. Altered permeability of the peritoneal membrane after using hypertonic peritoneal dialysis fluid. J Clin Invest 1969; 48:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/20\">",
"      Lindholm B, Werynski A, Bergstr&ouml;m J. Kinetics of peritoneal dialysis with glycerol and glucose as osmotic agents. ASAIO Trans 1987; 33:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/21\">",
"      Lysaght MJ, Hallett MD, Farrell PC. Evolution of transport theory in CAPD. Clin Nephrol 1988; 30 Suppl 1:S34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/22\">",
"      Krediet RT, Boeschoten EW, Zuyderhoudt FM, Arisz L. The relationship between peritoneal glucose absorption and body fluid loss by ultrafiltration during continuous ambulatory peritoneal dialysis. Clin Nephrol 1987; 27:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/23\">",
"      Struijk DG, Krediet RT, Koomen GC, et al. Indirect measurement of lymphatic absorption with inulin in continuous ambulatory peritoneal dialysis (CAPD) patients. Perit Dial Int 1990; 10:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/24\">",
"      Krediet RT, Struijk DG, Boeschoten EW, et al. Measurement of intraperitoneal fluid kinetics in CAPD patients by means of autologous haemoglobin. Neth J Med 1988; 33:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/25\">",
"      Paniagua R, Ventura Mde J, Rodr&iacute;guez E, et al. Impact of fill volume on peritoneal clearances and cytokine appearance in peritoneal dialysis. Perit Dial Int 2004; 24:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/26\">",
"      Renkin EM. Relation of capillary morphology to transport of fluid and large molecules: a review. Acta Physiol Scand Suppl 1979; 463:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/27\">",
"      Krediet RT, Struijk DG, Koomen GC, et al. The disappearance of macromolecules from the peritoneal cavity during continuous ambulatory peritoneal dialysis (CAPD) is not dependent on molecular size. Perit Dial Int 1990; 10:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/28\">",
"      Nolph KD, Twardowski ZJ, Popovich RP, Rubin J. Equilibration of peritoneal dialysis solutions during long-dwell exchanges. J Lab Clin Med 1979; 93:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/29\">",
"      Wang T, Waniewski J, Heimb&uuml;rger O, et al. A quantitative analysis of sodium transport and removal during peritoneal dialysis. Kidney Int 1997; 52:1609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/30\">",
"      Raja RM, Cantor RE, Boreyko C, et al. Sodium transport during ultrafiltration peritoneal dialysis. Trans Am Soc Artif Intern Organs 1972; 18:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/31\">",
"      Nolph KD, Hano JE, Teschan PE. Peritoneal sodium transport during hypertonic peritoneal dialysis. Physiologic mechanisms and clinical implications. Ann Intern Med 1969; 70:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/32\">",
"      Heimb&uuml;rger O, Waniewski J, Werynski A, Lindholm B. A quantitative description of solute and fluid transport during peritoneal dialysis. Kidney Int 1992; 41:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/33\">",
"      Imholz AL, Koomen GC, Struijk DG, et al. Fluid and solute transport in CAPD patients using ultralow sodium dialysate. Kidney Int 1994; 46:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/34\">",
"      Merchant MR, Hutchinson AJ, Butler SJ, et al. Calcium, magnesium mass transfer and lactate balance study in CAPD patients with reduced calcium/magnesium and high lactate dialysis fluid. Adv Perit Dial 1992; 8:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/35\">",
"      Martis L, Serkes KD, Nolph KD. Calcium carbonate as a phosphate binder: is there a need to adjust peritoneal dialysate calcium concentrations for patients using CaCO3? Perit Dial Int 1989; 9:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/36\">",
"      Uribarri J, Buquing J, Oh MS. Acid-base balance in chronic peritoneal dialysis patients. Kidney Int 1995; 47:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/37\">",
"      Twardowski ZJ, Prowant BF, Nolph KD, et al. High volume, low frequency continuous ambulatory peritoneal dialysis. Kidney Int 1983; 23:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/38\">",
"      Twardowski ZJ, Khanna R, Nolph KD, et al. Intraabdominal pressures during natural activities in patients treated with continuous ambulatory peritoneal dialysis. Nephron 1986; 44:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/39\">",
"      Imholz AL, Koomen GC, Struijk DG, et al. Effect of an increased intraperitoneal pressure on fluid and solute transport during CAPD. Kidney Int 1993; 44:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/40\">",
"      Ho-dac-Pannekeet MM, Schouten N, Langendijk MJ, et al. Peritoneal transport characteristics with glucose polymer based dialysate. Kidney Int 1996; 50:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/41\">",
"      Rippe B, Perry MA, Granger DN. Permselectivity of the peritoneal membrane. Microvasc Res 1985; 29:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/42\">",
"      Krediet RT, Imholz AL, Struijk DG, et al. Ultrafiltration failure in continuous ambulatory peritoneal dialysis. Perit Dial Int 1993; 13 Suppl 2:S59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/43\">",
"      Zakaria ER, Rippe B. Osmotic barrier properties of the rat peritoneal membrane. Acta Physiol Scand 1993; 149:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/44\">",
"      Leypoldt JK. Interpreting peritoneal membrane osmotic reflection coefficients using a distributed model of peritoneal transport. Adv Perit Dial 1993; 9:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/45\">",
"      Mactier RA, Khanna R, Twardowski Z, et al. Contribution of lymphatic absorption to loss of ultrafiltration and solute clearances in continuous ambulatory peritoneal dialysis. J Clin Invest 1987; 80:1311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/46\">",
"      Imholz AL, Koomen GC, Struijk DG, et al. Effect of dialysate osmolarity on the transport of low-molecular weight solutes and proteins during CAPD. Kidney Int 1993; 43:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/47\">",
"      Mistry CD, Gokal R. Optimal use of glucose polymer (icodextrin) in peritoneal dialysis. Perit Dial Int 1996; 16 Suppl 1:S104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/48\">",
"      Mistry CD, Gokal R, Peers E. A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis. Kidney Int 1994; 46:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/49\">",
"      Rippe B, Levin L. Computer simulations of ultrafiltration profiles for an icodextrin-based peritoneal fluid in CAPD. Kidney Int 2000; 57:2546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/50\">",
"      Douma CE, Hiralall JK, de Waart DR, et al. Icodextrin with nitroprusside increases ultrafiltration and peritoneal transport during long CAPD dwells. Kidney Int 1998; 53:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/51\">",
"      Heimb&uuml;rger O, Waniewski J, Werynski A, et al. Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int 1990; 38:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/52\">",
"      Pannekeet MM, Imholz AL, Struijk DG, et al. The standard peritoneal permeability analysis: a tool for the assessment of peritoneal permeability characteristics in CAPD patients. Kidney Int 1995; 48:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/53\">",
"      Pletinck A, Vanholder R, Veys N, Van Biesen W. Protecting the peritoneal membrane: factors beyond peritoneal dialysis solutions. Nat Rev Nephrol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/54\">",
"      Krediet RT, Struijk DG, Boeschoten EW, et al. The time course of peritoneal transport kinetics in continuous ambulatory peritoneal dialysis patients who develop sclerosing peritonitis. Am J Kidney Dis 1989; 13:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/55\">",
"      Krediet RT. Evaluation of peritoneal membrane integrity. J Nephrol 1997; 10:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/56\">",
"      Smit W, Struijk DG, Ho-Dac-Pannekeet MM, Krediet RT. Quantification of free water transport in peritoneal dialysis. Kidney Int 2004; 66:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/57\">",
"      La Milia V, Di Filippo S, Crepaldi M, et al. Mini-peritoneal equilibration test: A simple and fast method to assess free water and small solute transport across the peritoneal membrane. Kidney Int 2005; 68:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/58\">",
"      Michels WM, Zweers MM, Smit W, et al. Does lymphatic absorption change with the duration of peritoneal dialysis? Perit Dial Int 2004; 24:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/63/33784/abstract/59\">",
"      Imholz AL, Koomen GC, Voorn WJ, et al. Day-to-day variability of fluid and solute transport in upright and recumbent positions during CAPD. Nephrol Dial Transplant 1998; 13:146.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1878 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-FDF33D9AD5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_63_33784=[""].join("\n");
var outline_f32_63_33784=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10255146\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES OF TRANSPORT ACROSS THE PERITONEAL MEMBRANE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pores for solute transport",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Aquaporin-1 and water transport",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Solute transport",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Low molecular weight solutes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - High molecular weight solutes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Electrolytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Fluid transport",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL CORRELATES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Large or small peritoneal vascular surface area",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Impaired aquaporin-1-mediated water transport",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Assessment of aquaporin-1 function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Increased lymphatic absorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10255146\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1878\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1878|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/26/33198\" title=\"figure 1\">",
"      Solute removal in PD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/26/6574\" title=\"figure 2\">",
"      PET rapid vs slow transporters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/53/26461\" title=\"figure 3\">",
"      Changes in PD transport over time",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/9/34974\" title=\"figure 4\">",
"      Changes in PD sodium ratio",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/31/5623?source=related_link\">",
"      Peritoneal equilibration test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/50/23337?source=related_link\">",
"      Problems with solute clearance and ultrafiltration in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36215?source=related_link\">",
"      Rapid transporters on maintenance peritoneal dialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_63_33785="Fluoxetine: Pediatric drug information";
var content_f32_63_33785=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluoxetine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"    see \"Fluoxetine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/58/30630?source=see_link\">",
"    see \"Fluoxetine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F172714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      PROzac&reg;;",
"     </li>",
"     <li>",
"      PROzac&reg; Weekly&trade;;",
"     </li>",
"     <li>",
"      Sarafem&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F172715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Fluoxetine&reg;;",
"     </li>",
"     <li>",
"      Ava-Fluoxetine;",
"     </li>",
"     <li>",
"      CO Fluoxetine;",
"     </li>",
"     <li>",
"      Dom-Fluoxetine;",
"     </li>",
"     <li>",
"      Fluoxetine Capsules BP;",
"     </li>",
"     <li>",
"      FXT 40;",
"     </li>",
"     <li>",
"      Gen-Fluoxetine;",
"     </li>",
"     <li>",
"      JAMP-Fluoxetine;",
"     </li>",
"     <li>",
"      Mint-Fluoxetine;",
"     </li>",
"     <li>",
"      Mylan-Fluoxetine;",
"     </li>",
"     <li>",
"      Novo-Fluoxetine;",
"     </li>",
"     <li>",
"      Nu-Fluoxetine;",
"     </li>",
"     <li>",
"      PHL-Fluoxetine;",
"     </li>",
"     <li>",
"      PMS-Fluoxetine;",
"     </li>",
"     <li>",
"      PRO-Fluoxetine;",
"     </li>",
"     <li>",
"      Prozac&reg;;",
"     </li>",
"     <li>",
"      Q-Fluoxetine;",
"     </li>",
"     <li>",
"      ratio-Fluoxetine;",
"     </li>",
"     <li>",
"      Riva-Fluoxetine;",
"     </li>",
"     <li>",
"      Sandoz-Fluoxetine;",
"     </li>",
"     <li>",
"      Teva-Fluoxetine;",
"     </li>",
"     <li>",
"      ZYM-Fluoxetine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1052928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidepressant, Selective Serotonin Reuptake Inhibitor (SSRI)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1052920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"      see \"Fluoxetine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Upon discontinuation of fluoxetine therapy, gradually taper dose. If intolerable symptoms occur following a dose reduction, consider resuming the previously prescribed dose and/or decrease dose at a more gradual rate. If used for an extended period of time, long-term usefulness of fluoxetine should be periodically re-evaluated for the individual patient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Anxiety  with associated phobias and panic attacks:",
"     </b>",
"     Very limited data available: Children 2-6 years: Oral: 5 mg/dose or 0.25 mg/kg/dose once daily; adequate trial is considered to be 8-10 weeks; continuation of therapy should be evaluated at 6-9 months after initiation; dosing based on case report in a 2.5-year old child and expert recommendations (Gleason, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Bulimia nervosa adjunct therapy with cognitive behavioral therapy:",
"     </b>",
"     Limited data available: Children &ge;12 years and Adolescents: Oral: Initial: 20 mg once daily for 3 days, then 40 mg once daily for 3 days, then 60 mg once daily; dosing based on an open-label study of 10 pediatric patients (age: 12-18 years) which showed significant decrease in number of weekly purges; other reports describe use in adolescents (Gable, 2005; Kotler, 2003; Rosen, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Depression:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Manufacturer's labeling: Children &ge;8 years and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Lower weight Children: Oral: Initial: 10 mg once daily; usual daily dose: 10 mg/",
"     <b>",
"      day",
"     </b>",
"     ; if needed, may increase dose to 20 mg once daily after several weeks; maximum daily dose: 20 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Higher weight Children and Adolescents: Oral: Initial: 10-20 mg once daily; in patients started at 10 mg once daily, may increase dose to 20 mg after 1 week; maximum daily dose: 20 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Alternate dosing: Limited data available: Lower initial dosing has been recommended by some experts (Dopheide, 2006; Gleason, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children &le;11 years: Oral: Initial: 5 mg once daily; clinically, doses have been titrated up to 40 mg once daily in pediatric patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children &ge;12 years and Adolescents: Oral: Initial: 10 mg once daily; clinically, doses have been titrated up to 40 mg once daily in pediatric patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Obsessive-compulsive disorder:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &lt;7 years: Limited data available: Oral: Initial: 5 mg once daily (Gleason, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &ge;7 years and Adolescents: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Lower weight Children: Initial: 10 mg once daily; if needed, may increase dose after several weeks; usual daily dose: 20-30 mg/",
"     <b>",
"      day",
"     </b>",
"     ; minimal experience with doses &gt;20 mg/",
"     <b>",
"      day",
"     </b>",
"     ; no experience with doses &gt;60 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Higher weight Children and Adolescents: Initial: 10 mg once daily; increase dose to 20 mg once daily after 2 weeks; may increase dose after several more weeks, if needed; usual daily dose: 20-60 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Repetitive behavior associated with autism spectrum disorders (ASD):",
"     </b>",
"     Limited data available: Children &ge;5 years and Adolescents: Oral: Initial: 2.5 mg once daily for 7 days; then may titrate at weekly intervals using weight-based dosing: 0.3 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     during week 2; followed by 0.5 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     during week 3, up to a maximum of 0.8 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     ; dosing based on a double-blind, crossover, placebo-controlled trial in 39 pediatric patients (age: 5-16 years) which showed statistically significant improvement in behavior scores compared to placebo; mean final dose: 9.9 mg/",
"     <b>",
"      day",
"     </b>",
"     (range: 2.4-20 mg/",
"     <b>",
"      day",
"     </b>",
"     ) or 0.36 &plusmn; 0.116 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     (Hollander, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Selective mutism:",
"     </b>",
"     Limited data available: Children &ge;5 years and Adolescents: Oral: Initial: 5 mg once daily for 7 days, then increase to 10 mg daily for 7 days, and then increase to 20 mg daily;  may further titrate in 20 mg/",
"     <b>",
"      day",
"     </b>",
"     increments if needed every 2 weeks; maximum daily dose: 60 mg/",
"     <b>",
"      day",
"     </b>",
"     . Dosing is based on an open-label study of 21 pediatric patients (age: 5-14 years); positive responses were reported in 76% of patients and required a dose of at least 20 mg/",
"     <b>",
"      day",
"     </b>",
"     ; mean final dose: 28.1 mg/",
"     <b>",
"      day",
"     </b>",
"     (1.1 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     ) (Dummitt, 1996). Weight-based dosing has been reported in a double-blind placebo-controlled trial (treatment group: n=6; placebo: n=9; age: 6-12 years) using the following titration: 0.2 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     for 1 week, then 0.4 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     for 1 week, then 0.6 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     for 10 weeks; mean final dose: 21.4 mg/",
"     <b>",
"      day",
"     </b>",
"     (Black,1994). To fully assess therapeutic response, a therapeutic trial of at least 9-12 weeks or longer has been suggested (Black, 1994; Dummitt; 1996; Kaakeh, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"     <b>",
"      Depression, obsessive-compulsive disorder, premenstrual dysphoric disorder, bulimia:",
"     </b>",
"     Oral: Initial: 20 mg once daily in the morning; may increase after several weeks by 20 mg/",
"     <b>",
"      day",
"     </b>",
"     increments; maximum daily dose: 80 mg/",
"     <b>",
"      day",
"     </b>",
"     ; doses &gt;20 mg may be given once daily or divided twice daily.",
"     <b>",
"      Note:",
"     </b>",
"     Lower doses of 5-10 mg/",
"     <b>",
"      day",
"     </b>",
"     have been used for initial treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Bulimia nervosa:",
"     </b>",
"     Oral: 60 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Depression:",
"     </b>",
"     Oral: Initial: 20 mg once daily; may increase after several weeks if inadequate response (maximum: 80 mg/",
"     <b>",
"      day",
"     </b>",
"     ). Patients maintained on Prozac&reg; 20 mg/day may be changed to Prozac&reg; Weekly&trade; 90 mg/week, starting dose 7 days after the last 20 mg/day dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Depression associated with bipolar disorder (in combination with olanzapine):",
"     </b>",
"     Oral: Initial: 20 mg in the evening; adjust as tolerated to usual range of 20-50 mg/",
"     <b>",
"      day",
"     </b>",
"     . See",
"     <b>",
"      \"Note\"",
"     </b>",
"     below.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Obsessive-compulsive disorder:",
"     </b>",
"     Oral: Initial: 20 mg once daily; may increase after several weeks if inadequate response; recommended range: 20-60 mg/",
"     <b>",
"      day",
"     </b>",
"     (maximum daily dose: 80 mg/",
"     <b>",
"      day",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Panic disorder:",
"     </b>",
"     Oral: Initial: 10 mg once daily; after 1 week, increase to 20 mg/",
"     <b>",
"      day",
"     </b>",
"     ; may increase after several weeks; doses &gt;60 mg/",
"     <b>",
"      day",
"     </b>",
"     have not been evaluated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Premenstrual dysphoric disorder (Sarafem&reg;):",
"     </b>",
"     Oral: 20 mg once daily continuously",
"     <b>",
"      or",
"     </b>",
"     20 mg once daily starting 14 days prior to menstruation and through first full day of menses (repeat with each cycle)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Treatment-resistant depression (in combination with olanzapine):",
"     </b>",
"     Oral: Initial: 20 mg in the evening; adjust as tolerated to usual range of 20-50 mg/",
"     <b>",
"      day",
"     </b>",
"     . See",
"     <b>",
"      \"Note\"",
"     </b>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     When using individual components of fluoxetine with olanzapine rather than fixed dose combination product (Symbyax&reg;), approximate dosage correspondence is as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Olanzapine 2.5 mg + fluoxetine 20 mg = Symbyax&reg; 3/25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Olanzapine 5 mg + fluoxetine 20 mg = Symbyax&reg; 6/25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Olanzapine 12.5 mg + fluoxetine 20 mg = Symbyax&reg; 12/25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Olanzapine 5 mg + fluoxetine 50 mg = Symbyax&reg; 6/50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Olanzapine 12.5 mg + fluoxetine 50 mg = Symbyax&reg; 12/50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Children, Adolescents, and Adults: Adjustment not routinely needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Single dose studies: Adults: Pharmacokinetics of fluoxetine and norfluoxetine were similar among subjects with all levels of impaired renal function, including anephric patients on chronic hemodialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Chronic administration: Additional accumulation of fluoxetine or norfluoxetine may occur in patients with severely impaired renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children and Adolescents: Elimination half-life of fluoxetine is prolonged in patients with hepatic impairment; lower doses or less frequent administration are recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: Elimination half-life of fluoxetine is prolonged in patients with hepatic impairment; lower doses or less frequent administration are recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cirrhosis patient: Administer a lower dose or less frequent dosing interval",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Compensated cirrhosis without ascites: Administer 50% of normal dose",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F172686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 10 mg, 20 mg, 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PROzac&reg;: 10 mg, 20 mg, 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, delayed release, enteric coated pellets, oral: 90 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PROzac&reg; Weekly&trade;: 90 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 20 mg/5 mL (5 mL, 120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 10 mg, 20 mg, 60 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sarafem&reg;: 10 mg, 15 mg, 20 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F172670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7873368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Prozac&reg; &amp; Prozac&reg; Weekly&trade;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088999.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088999.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Sarafem&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089119.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089119.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1052933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May be administered without regard to food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indication specific:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Major depressive disorder and obsessive compulsive disorder: Take in the morning; if twice daily dosing, take at morning and noon",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Bipolar I disorder and treatment-resistant depression (with concurrent olanzapine): Take in the evening",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Bulimia: Take in the morning",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1052923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     All dosage forms should be stored at controlled room temperature; protect from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1052932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment (acute and maintenance) of major depressive disorder (FDA approved in ages &ge;8 years and adults); treatment (acute and maintenance) of obsessive-compulsive disorder (FDA approved in ages &ge;7 years and adults); treatment of bulimia nervosa (FDA approved in adults); treatment of panic disorder with or without agoraphobia (FDA approved in adults); treatment of  premenstrual dysphoric disorder (PMDD) (Sarafem&reg;: FDA approved in adults); has also been used for anxiety and/or selective mutism and repetitive behavior associated with an autism spectrum disorder (eg, autism, Asperger&rsquo;s syndrome, pervasive developmental disorders)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F172774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       FLUoxetine may be confused with DULoxetine, famotidine, Feldene&reg;, fluconazole, fluvastatin, fluvoxaMINE, fosinopril, furosemide, PARoxetine, thiothixene",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       PROzac&reg; may be confused with Paxil&reg;, Prelone&reg;, PriLOSEC&reg;, Prograf&reg;, Proscar&reg;, ProSom, Provera&reg;",
"      </p>",
"      <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"       Sarafem&reg; may be confused with Serophene&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Reneuron [Spain] may be confused with Remeron brand name for mirtazapine [U.S., Canada, and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F172770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, hemorrhage, hypertension, palpitation, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Abnormal dreams, abnormal thinking, agitation, amnesia, anxiety, chills, confusion, dizziness, emotional lability, headache, insomnia, nervousness, sleep disorder, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Ejaculation abnormal, impotence, libido decreased, menorrhagia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, appetite decreased, constipation, diarrhea, dyspepsia, flatulence, nausea, taste perversion, thirst, vomiting, weight gain, weight loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary frequency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Hyperkinesia, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Vision abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Ear pain, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pharyngitis, sinusitis, yawn",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, epistaxis, flu-like syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acne, acute abdominal syndrome, akathisia, albuminuria, allergies, alopecia, amenorrhea, anaphylactoid reactions, anemia, angina, aphthous stomatitis, aplastic anemia, arrhythmia, arthritis, asthma, ataxia, atrial fibrillation, balance disorder, bone pain, bruising, bruxism, bursitis, cardiac arrest, cataract, cerebrovascular accident, CHF, cholelithiasis, cholestatic jaundice, colitis, dehydration, delusions, depersonalization, dyskinesia, dysphagia, dysuria, ecchymosis, edema, eosinophilic pneumonia, erythema multiforme, erythema nodosum, esophagitis, euphoria, exfoliative dermatitis, extrapyramidal symptoms (rare), gastritis, gastroenteritis, GI ulcer, glossitis, gout, gynecological bleeding, gynecomastia, hallucinations, hepatic failure/necrosis, hepatitis, hiccup, hostility, hypercholesteremia, hyperprolactinemia, hypertonia, hyperventilation, hypoglycemia, hypokalemia, hyponatremia (possibly in association with SIADH), hypotension, hypothyroidism, immune-related hemolytic anemia, kidney failure, laryngospasm, laryngeal edema, leg cramps, liver function test abnormalities, lupus-like syndrome, malaise, melena, migraine, misuse/abuse, MI, mydriasis, myoclonus, neuroleptic malignant syndrome (NMS), optic neuritis, orthostatic hypotension, pancreatitis, pancytopenia, paranoid reaction, petechia, photosensitivity reaction, priapism, pulmonary embolism, pulmonary fibrosis, pulmonary hypertension, purpuric rash, QT prolongation, serotonin syndrome, Stevens-Johnson syndrome, suicidal ideation, syncope, tachycardia, thrombocytopenia, thrombocytopenic purpura, toxic epidermal necrolysis, vasculitis, ventricular tachycardia (including torsade de pointes), violent behavior",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1052938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fluoxetine or any component; use of MAO inhibitors within 14 days (potentially fatal reactions may occur; do not use MAO inhibitors for at least 5 weeks after fluoxetine is discontinued); concurrent use of thioridazine or use within 5 weeks after fluoxetine is discontinued; concurrent use of pimozide",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1052919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause abnormal bleeding (eg, ecchymosis, purpura, upper GI bleeding); use with caution in patients with impaired platelet aggregation and with concurrent use of aspirin, NSAIDs, or other drugs that affect coagulation. A recent report describes five children (age: 8-15 years) who developed epistaxis (n=4) or bruising (n=1) while receiving SSRI therapy (sertraline) (Lake, 2000). May cause insomnia, anxiety, or nervousness. May impair cognitive or motor performance. Use with caution in patients with hepatic impairment; dosage reduction required. Use with caution in renal  impairment, seizure disorders, cardiac dysfunction, diabetes mellitus. Use with caution in patients receiving diuretics or those who are volume-depleted (may cause hyponatremia or SIADH). May cause mydriasis; use with caution in patients at risk of acute narrow-angle glaucoma or with increased intraocular pressure.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     May cause anorexia or weight loss; use with caution in patients where weight loss is undesirable. Fluoxetine may cause decreased growth (smaller increases in weight and height) in children and adolescent patients; currently, no studies directly evaluate fluoxetine's long-term effects on growth, development, and maturation of pediatric patients; periodic monitoring of height and weight in pediatric patients is recommended. Case reports of decreased growth in children receiving fluoxetine or fluvoxamine (n=4; age: 11.6-13.7 years) for 6 months to 5 years suggest a suppression of growth hormone secretion during SSRI therapy (Weintrob, 2002). Further studies are needed. SSRI-associated vomiting is two- to threefold more prevalent in children compared to adolescents and is more prevalent in adolescents compared to adults (Safer, 2006).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Significant toxicities have been observed after exposure to fluoxetine in juvenile animals (some occurring at clinically relevant doses). Toxicities included myotoxicity (eg, skeletal muscle damage and necrosis, elevated serum CPK), impaired bone development, and long-term neurobehavioral and reproductive toxicity. The clinical significance of these findings is uncertain.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1052918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clinical worsening of depression or suicidal ideation and behavior may occur in children and adults with major depressive disorder",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . In clinical trials, antidepressants increased the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (18-24 years of age) with major depressive disorder and other psychiatric disorders. This risk must be considered before prescribing antidepressants for any clinical use. Short-term studies did",
"     <b>",
"      not",
"     </b>",
"     show an increased risk of suicidality with antidepressant use in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Patients of all ages who are treated with antidepressants for any indication require appropriate monitoring and close observation for clinical worsening of depression, suicidality, and unusual changes in behavior, especially during the first few months after antidepressant initiation or when the dose is adjusted. Family members and caregivers should be instructed to closely observe the patient (ie, daily) and communicate condition with healthcare provider. Patients should also be monitored for associated behaviors (eg, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, mania) which may increase the risk for worsening depression or suicidality. Worsening depression or emergence of suicidality (or associated behaviors listed above) that is abrupt in onset, severe, or not part of the presenting symptoms, may require discontinuation or modification of drug therapy. SSRI-associated behavioral activation (ie, restlessness, hyperkinesis, hyperactivity, agitation) is two- to threefold more prevalent in children compared to adolescents; it is more prevalent in adolescents compared to adults. Somnolence (including sedation and drowsiness) is more common in adults compared to children and adolescents (Safer, 2006).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Avoid abrupt discontinuation; discontinuation symptoms (including agitation, dysphoria, anxiety, confusion, dizziness, hypomania, nightmares, and other symptoms) may occur if therapy is abruptly discontinued or dose reduced; taper the dose to minimize risks of discontinuation symptoms; if intolerable symptoms occur following a decrease in dosage or upon discontinuation of therapy, consider resuming the previous dose with a more gradual taper. To reduce risk of intentional overdose, write prescriptions for the smallest quantity consistent with good patient care. Screen individuals for bipolar disorder prior to treatment (using antidepressants alone may induce manic episodes in patients with this condition). Potentially fatal serotonin syndrome may occur when SSRIs are used in combination with serotonergic drugs (eg, triptans) or drugs that impair the metabolism of serotonin (eg, MAO inhibitors).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Rash or urticaria may occur along with leukocytosis, fever, edema, arthralgia, lymphadenopathy, respiratory distress, and other symptoms; rare cases of vasculitis and lupus-like syndrome have been reported; anaphylactoid reactions including laryngospasm, bronchospasm, angioedema, and urticaria may occur; discontinue use if rash or other allergic reaction occurs.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Persistent pulmonary hypertension of the newborn (PPHN) has been reported with use during pregnancy; the FDA has reviewed further studies and data evaluating this risk which have shown conflicting results. The FDA has concluded that based on available data, it is unclear whether SSRI use during pregnancy causes PPHN. Neonates born to women receiving SSRIs later during the third trimester may experience respiratory distress, apnea, cyanosis, temperature instability, vomiting, feeding difficulty, hypoglycemia, constant crying, irritability, hypotonia, hypertonia, hyper-reflexia, tremor, jitteriness, and seizures; these symptoms may be due to a direct toxic effect, withdrawal syndrome, or (in some cases) serotonin syndrome. Withdrawal symptoms occur in 30% of neonates exposed to SSRIs",
"     <i>",
"      in utero",
"     </i>",
"     ; monitor newborns for at least 48 hours after birth; long-term effects of",
"     <i>",
"      in utero",
"     </i>",
"     exposure to SSRIs are unknown (Levinson-Castiel, 2006).  Use with caution during third trimester of pregnancy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Oral solution contains benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; avoid use of fluoxetine products containing benzoic acid in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F172756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (major), CYP2D6 (major), CYP2E1 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (moderate), CYP2B6 (weak), CYP2C19 (moderate), CYP2C9 (weak), CYP2D6 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F172679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Management: Patients receiving selective serotonin reuptake inhibitors should be advised to avoid alcohol.  Monitor for increased psychomotor impairment in patients who consume alcohol during treatment with selective serotonin reuptake inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist). This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: FLUoxetine may enhance the adverse/toxic effect of ARIPiprazole. Specifically, the risk of risk of neuroleptic malignant syndrome may be increased. ARIPiprazole may enhance the serotonergic effect of FLUoxetine. This could result in serotonin syndrome. FLUoxetine may increase the serum concentration of ARIPiprazole.  Management: Aripiprazole dose should be reduced by at least half, except when used adjunctively for depression. Consult full interaction monograph or aripiprazole prescribing information for complete details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Aspirin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of AtoMOXetine.  Management: Initiate atomoxetine at a reduced dose (adult doses -- patients up to 70kg: 0.5mg/kg/day; patients 70kg or more: 40mg/day) in patients receiving a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Acebutolol; Atenolol; Betaxolol (Ophthalmic); Betaxolol (Systemic); Bisoprolol; Carteolol (Ophthalmic); Esmolol; Labetalol; Levobunolol; Metipranolol; Nadolol; Penbutolol; Sotalol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Selective Serotonin Reuptake Inhibitors. Specifically those agents metabolized via CYP1A2, 2C, and/or 3A4 isoenzymes. Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CarBAMazepine. Specifically those SSRIs that inhibit CYP3A4 isoenzymes.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of CloZAPine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Moderate) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Moderate) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Strong) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproheptadine: May diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dextromethorphan: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Dextromethorphan. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Dextromethorphan.  Management: Avoid the concurrent use of dextromethorphan and SSRIs, particularly fluoxetine and paroxetine, when possible.  The risk for this interaction may persist for several weeks following discontinuation of fluoxetine or paroxetine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: FLUoxetine may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Galantamine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Galantamine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: FLUoxetine may enhance the QTc-prolonging effect of Haloperidol. FLUoxetine may increase the serum concentration of Haloperidol.  Management: Consider alternatives to this combination when available.  If the combination is used, monitor for evidence of QTc prolongation and increased systemic haloperidol concentrations/effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: Selective Serotonin Reuptake Inhibitors may enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents.  Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Selective Serotonin Reuptake Inhibitors may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Selective Serotonin Reuptake Inhibitors may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could increase the risk of serotonin toxicity/serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Selective Serotonin Reuptake Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Methadone. Fluvoxamine appears to be the only interacting SSRI.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with selective serotonin reuptake inhibitors for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mexiletine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Mexiletine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NIFEdipine: FLUoxetine may enhance the adverse/toxic effect of NIFEdipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NiMODipine: FLUoxetine may increase the serum concentration of NiMODipine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of NSAID (COX-2 Inhibitor). NSAID (COX-2 Inhibitor) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.  Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of FLUoxetine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: FLUoxetine may increase the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: This combination may be used with caution only if the moderate CYP1A2 inhibitor does not significantly inhibit other CYP enzymes and the patient is not taking any other drugs that do significantly inhibit other specific CYP enzymes.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: FLUoxetine may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of QuiNIDine. Fluvoxamine appears to be the only SSRI of concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RisperiDONE: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of RisperiDONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased.  Management: Tetrabenazine adult dose should be reduced by 50% when starting a strong CYP2D6 inhibitor.  Maximum tetrabenazine adult dose is 50 mg/day when used with a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Selective Serotonin Reuptake Inhibitors may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol. TraMADol may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Selective Serotonin Reuptake Inhibitors may decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tryptophan: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1052941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tryptophan supplements may increase CNS and GI adverse effects (eg, restlessness, agitation, GI problems); concurrent use is",
"     <b>",
"      not recommended",
"     </b>",
"     . Food does not affect bioavailability, but may delay absorption by 1-2 hours",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F172681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F172698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies. Fluoxetine and its metabolite cross the human placenta. An increased risk of teratogenic effects, including cardiovascular defects, may be associated with maternal use of fluoxetine or other SSRIs; however, available information is conflicting. Nonteratogenic effects in the newborn following SSRI/SNRI exposure late in the third trimester include respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypo- or hypertonia, hyper-reflexia, jitteriness, irritability, constant crying, and tremor. Symptoms may be due to the toxicity of the SSRIs/SNRIs or a discontinuation syndrome and may be consistent with serotonin syndrome associated with SSRI treatment. Persistent pulmonary hypertension of the newborn (PPHN) has also been reported with SSRI exposure. The long-term effects of",
"     <i>",
"      in utero",
"     </i>",
"     SSRI exposure on infant development and behavior are not known.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Due to pregnancy-induced physiologic changes, women who are pregnant may require dose adjustments of fluoxetine to achieve euthymia. The ACOG recommends that therapy with SSRIs or SNRIs during pregnancy be individualized; treatment of depression during pregnancy should incorporate the clinical expertise of the mental health clinician, obstetrician, primary healthcare provider, and pediatrician. According to the American Psychiatric Association (APA), the risks of medication treatment should be weighed against other treatment options and untreated depression. For women who discontinue antidepressant medications during pregnancy and who may be at high risk for postpartum depression, the medications can be restarted following delivery. Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1052927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver function, weight, serum glucose; serum sodium (in volume depleted patients); monitor for rash and signs or symptoms of anaphylactoid reactions; monitor height and weight in pediatric patients periodically. Monitor patient periodically for symptom resolution; monitor for worsening depression, suicidality, and associated behaviors (especially at the beginning of therapy or when doses are increased or decreased)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1052931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Therapeutic levels have not been well established:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Therapeutic: Fluoxetine 100-800 ng/mL (SI: 289-2314 nmol/L); norfluoxetine 100-600 ng/mL (SI: 289-1735 nmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Toxic: (Fluoxetine plus norfluoxetine): &gt;2000 ng/mL (SI: &gt;5784 nmol/L)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1052917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits CNS neuron serotonin uptake; minimal or no effect on reuptake of norepinephrine or dopamine; does not significantly bind to alpha-adrenergic, histamine or cholinergic receptors; may therefore be useful in patients at risk from sedation, hypotension and anticholinergic effects of tricyclic antidepressants",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1052936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maximum effect: Antidepressant: Usually occur after &gt;4 weeks; due to long half-life, resolution of adverse reactions after discontinuation may be slow",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1052937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Average steady-state fluoxetine serum concentrations in children (n=10; 6 to &lt;13 years of age) were 2-fold higher than in adolescents (n=11; 13 to &lt;18 years of age); all patients received 20 mg/day; average steady-state norfluoxetine serum concentrations were 1.5-fold higher in the children compared with adolescents; differences in weight almost entirely explained the differences in serum concentrations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Well absorbed; enteric-coated pellets contained in Prozac&reg; Weekly&trade; resist dissolution until GI pH &gt;5.5 and therefore delay onset of absorption 1-2 hours compared to immediate release formulations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 12-43 L/kg; widely distributed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &sim;95% (albumin and alpha",
"     <sub>",
"      1",
"     </sub>",
"     -glycoprotein)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, via CYP2C19  and 2D6, to norfluoxetine (activity equal to fluoxetine) and other metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Capsules, tablets, solution, and weekly capsules are bioequivalent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fluoxetine: Acute dosing: 1-3 days; chronic dosing: 4-6 days; cirrhosis: 7.6 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Norfluoxetine: Acute and chronic dosing: 4-16 days; cirrhosis: 12 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Immediate release formulation: After 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (10% as norfluoxetine, 2.5% to 5% as fluoxetine)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dialysis: Not removed by hemodialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Weekly formulation results in greater fluctuations between peak and trough concentrations of fluoxetine and norfluoxetine compared to once-daily dosing (24% daily/164% weekly; 17% daily/43% weekly, respectively). Trough concentrations are 76% lower for fluoxetine and 47% lower for norfluoxetine than the concentrations maintained by 20 mg once-daily dosing. Steady-state fluoxetine concentrations are ~50% lower following the once-weekly regimen compared to 20 mg once daily.",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1052925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/58/30630?source=see_link\">",
"      see \"Fluoxetine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide received with each prescription and refill of fluoxetine. It may take 2-3 weeks, maybe even longer, to achieve desired results. An increased risk of suicidal thinking and behavior has been reported with the use of antidepressants in children, adolescents, and young adults (18-24 years of age). Notify physician if you experience feelings of being more depressed, have thoughts of suicide, or become more agitated or irritable. Avoid alcohol, tryptophan supplements, and the herbal medicine St John's wort; avoid aspirin, NSAIDs, or other drugs that affect coagulation (may increase risks of bleeding); may cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth; inform physician immediately if hives or rash develops. Some medicines should not be taken with fluoxetine or should not be taken for a while after fluoxetine has been discontinued; inform healthcare professionals of other medications, nonprescription medications, and herbal or natural products being used. Take as directed; do not alter dose or frequency without consulting prescriber, avoid abrupt discontinuation.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F172692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Commercial oral solution is available (4 mg/mL)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 1 mg/mL fluoxetine oral solution may be prepared using the commercially available preparation (4 mg/mL). In separate graduated cylinders, measure 5 mL of the commercially available fluoxetine preparation and 15 mL of Simple Syrup, NF. Mix thoroughly in incremental proportions. For a 2 mg/mL solution, mix equal proportions of both the commercially available fluoxetine preparation and Simple Syrup, NF. Label \"refrigerate\". Both concentrations are stable for up to 56 days.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Black B and Uhde TW, &ldquo;Treatment of Elective Mutism With Fluoxetine: A Double Blind, Placebo-Controlled Study,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1994, 33(7):1000-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/63/33785/abstract-text/7961338/pubmed\" id=\"7961338\" target=\"_blank\">",
"        7961338",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al, &ldquo;Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 354(6):579-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/63/33785/abstract-text/16467545 /pubmed\" id=\"16467545 \" target=\"_blank\">",
"        16467545",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DeSilva KE, Le Flore DB, Marston BJ, et al, &ldquo;Serotonin Syndrome in HIV-Infected Individuals Receiving Antiretroviral Therapy and Fluoxetine,&rdquo;",
"      <i>",
"       AIDS",
"      </i>",
"      , 2001, 15(10):1281-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/63/33785/abstract-text/11426073/pubmed\" id=\"11426073\" target=\"_blank\">",
"        11426073",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dopheide JA, \"Recognizing and Treating Depression in Children and Adolescents,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2006, 63(3):233-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/63/33785/abstract-text/16434782/pubmed\" id=\"16434782\" target=\"_blank\">",
"        16434782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dow SP, Sonies BC, Scheib D, et al, \"Practical Guidelines for the Assessment and Treatment of Selective Mutism,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1995, 34(7):836-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/63/33785/abstract-text/7649953/pubmed\" id=\"7649953\" target=\"_blank\">",
"        7649953",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dummit ES 3rd, Klein RG, Tancer NK, et al, \"Fluoxetine Treatment of Children With Selective Mutism: An Open Trial,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1996, 35(5):615-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/63/33785/abstract-text/8935208/pubmed\" id=\"8935208\" target=\"_blank\">",
"        8935208",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gable KN and Dopheide JA, &ldquo;Psychotropic Medication Use at a Private Eating Disorders Treatment Facility: A Retrospective Chart Review and Descriptive Data Analysis,&rdquo;",
"      <i>",
"       Curr Ther Res Clin Exp",
"      </i>",
"      , 2005, 66:572-88.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gleason MM, Egger HL, Emslie GJ, et al, \"Psychopharmacological Treatment for Very Young Children: Contexts and Guidelines,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2007, 46(12):1532-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/63/33785/abstract-text/18030077/pubmed\" id=\"18030077\" target=\"_blank\">",
"        18030077",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hollander E, Phillips A, Chaplin W, et al, \"A Placebo Controlled Crossover Trial of Liquid Fluoxetine on Repetitive Behaviors in Childhood and Adolescent Autism,\"",
"      <i>",
"       Neuropsychopharmacology",
"      </i>",
"      , 2005, 30(3):582-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/63/33785/abstract-text/15602505/pubmed\" id=\"15602505\" target=\"_blank\">",
"        15602505",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaakeh Y and Stumpf JL, \"Treatment of Selective Mutism: Focus on Selective Serotonin Reuptake Inhibitors,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2008, 28(2):214-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/63/33785/abstract-text/18225967/pubmed\" id=\"18225967\" target=\"_blank\">",
"        18225967",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kotler LA, Devlin MJ, Davies M, et al, \"An Open Trial of Fluoxetine for Adolescents With Bulimia Nervosa,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2003, 13(3):329-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/63/33785/abstract-text/14642021/pubmed\" id=\"14642021\" target=\"_blank\">",
"        14642021",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lake MB, Birmaher B, Wassick S, et al, &ldquo;Bleeding and Selective Serotonin Reuptake Inhibitors in Childhood and Adolescence,&rdquo;",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2000, 10(1):35-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/63/33785/abstract-text/10755580/pubmed\" id=\"10755580\" target=\"_blank\">",
"        10755580",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levinson-Castiel R, Merlob P, Linder N, et al, \"Neonatal Abstinence Syndrome After",
"      <i>",
"       in utero",
"      </i>",
"      Exposure to Selective Serotonin Reuptake Inhibitors in Term Infants,\"",
"      <i>",
"       Arch Pediatr Adolesc Med",
"      </i>",
"      , 2006, 160(2):173-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/63/33785/abstract-text/16461873/pubmed\" id=\"16461873\" target=\"_blank\">",
"        16461873",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McPheeters ML, Warren Z, Sathe N, et al, \"A Systematic Review of Medical Treatments for Children With Autism Spectrum Disorders,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2011, 127(5):e1312-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/63/33785/abstract-text/21464191/pubmed\" id=\"21464191\" target=\"_blank\">",
"        21464191",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rosen DS and American Academy of Pediatrics Committee on Adolescence, \"Identification and Management of Eating Disorders in Children and Adolescents,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2010, 126(6):1240-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/63/33785/abstract-text/21115584/pubmed\" id=\"21115584\" target=\"_blank\">",
"        21115584",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Safer DJ and Zito JM, \"Treatment Emergent Adverse Effects of Selective Serotonin Reuptake Inhibitors by Age Group: Children vs. Adolescents,&rdquo;",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2006, 16(1/2):159-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/63/33785/abstract-text/16553536/pubmed\" id=\"16553536\" target=\"_blank\">",
"        16553536",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weintrob N, Cohen D, Klipper-Aurbach Y, et al, &ldquo;Decreased Growth During Therapy With Selective Serotonin Reuptake Inhibitors,&rdquo;",
"      <i>",
"       Arch Pediatr Adolesc Med",
"      </i>",
"      , 2002, 156(7):696-701.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/63/33785/abstract-text/12090838/pubmed\" id=\"12090838\" target=\"_blank\">",
"        12090838",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13315 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-61.234.146.186-EF0408A01F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_63_33785=[""].join("\n");
var outline_f32_63_33785=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708805\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172714\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172715\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052928\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052920\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172686\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172670\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7873368\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052933\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052923\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052932\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172774\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172770\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052938\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052919\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052918\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172756\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172679\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052941\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172681\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172698\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052927\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052931\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052917\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052936\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052937\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052925\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172692\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13315\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13315|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=related_link\">",
"      Fluoxetine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/58/30630?source=related_link\">",
"      Fluoxetine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_63_33786="Insulinoma Light";
var content_f32_63_33786=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F68737%7EENDO%2F56940&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F68737%7EENDO%2F56940&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Insulinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 271px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vascular insulinoma (left) abutting on normal pancreatic tissue (x 6).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of F John Service, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 482px\">",
"   <div class=\"ttl\">",
"    Insulinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 462px; height: 178px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Insulin staining of normal pancreas (left panel) and an insulin-secreting pancreatic tumor (right panel) (x 40).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of F John Service, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_63_33786=[""].join("\n");
var outline_f32_63_33786=null;
var title_f32_63_33787="Viral gastroenteritis epi";
var content_f32_63_33787=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F80471&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F80471&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differentiating features among viral causes of gastroenteritis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Viruses",
"       </td>",
"       <td class=\"subtitle1\">",
"        Predominant season",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Duration, days",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lactose intolerance",
"       </td>",
"       <td class=\"subtitle1\">",
"        Common modes of transmission in order of frequency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rotaviruses",
"       </td>",
"       <td>",
"        Fall/winter",
"       </td>",
"       <td>",
"        6 to 24 months",
"       </td>",
"       <td>",
"        5 to 7",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Fecal-oral; respiratory?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Caliciviruses",
"       </td>",
"       <td>",
"        All year (winter)",
"       </td>",
"       <td>",
"        All ages",
"       </td>",
"       <td>",
"        1 to 4",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Fecal-oral, water; shellfish, foods, respiratory?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Astroviruses",
"       </td>",
"       <td>",
"        Winter",
"       </td>",
"       <td>",
"        All ages",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Fecal-oral, water",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enteric adenoviruses",
"       </td>",
"       <td>",
"        Summer",
"       </td>",
"       <td>",
"        Children",
"       </td>",
"       <td>",
"        6 to 9",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Fecal-oral",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_63_33787=[""].join("\n");
var outline_f32_63_33787=null;
var title_f32_63_33788="Indications for GBS intrapartum antibiotic prophylaxis";
var content_f32_63_33788=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66582&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66582&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications and nonindications for intrapartum antibiotic prophylaxis to prevent early-onset group B streptococcal (GBS) disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Intrapartum GBS prophylaxis indicated",
"       </td>",
"       <td class=\"subtitle1\">",
"        Intrapartum GBS prophylaxis not indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Previous infant with invasive GBS disease",
"       </td>",
"       <td>",
"        Colonization with GBS during a previous pregnancy (unless an indication for GBS prophylaxis is present for current pregnancy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GBS bacteriuria during any trimester of the current pregnancy*",
"       </td>",
"       <td>",
"        GBS bacteriuria during previous pregnancy (unless an indication for GBS prophylaxis is present for current pregnancy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Positive GBS vaginal-rectal screening culture in late gestation",
"        <sup>",
"         &Delta;",
"        </sup>",
"        during current pregnancy*",
"       </td>",
"       <td>",
"        Negative vaginal and rectal GBS screening culture in late gestation&Delta; during the current pregnancy, regardless of intrapartum risk factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unknown GBS status at the onset of labor (culture not done, incomplete, or results unknown) and any of the following:",
"        <ul>",
"         <li>",
"          Delivery at &lt;37 weeks' gestation&loz;",
"         </li>",
"         <li>",
"          Amniotic membrane rupture &ge;18 hours",
"         </li>",
"         <li>",
"          Intrapartum temperature &ge;100.4&deg;F (&ge;38.0&deg;C)",
"          <sup>",
"           &sect;",
"          </sup>",
"         </li>",
"         <li>",
"          Intrapartum NAAT",
"          <sup>",
"           ������",
"          </sup>",
"          positive for GBS",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        Cesarean delivery performed before onset of labor on a woman with intact amniotic membranes, regardless of GBS colonization status or gestational age",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NAAT: nucleic acid amplification tests.",
"     <br>",
"      * Intrapartum antibiotic prophylaxis is not indicated in this circumstance if a cesarean delivery is performed before onset of labor on a woman with intact amniotic membranes.",
"      <br>",
"       &Delta; Optimal timing for prenatal GBS screening is at 35 to 37 weeks' gestation.",
"       <br>",
"        <font class=\"lozenge\">",
"         &loz;",
"        </font>",
"        Recommendations for the use of intrapartum antibiotics for prevention of early-onset GBS disease in the setting of threatened preterm delivery are discussed separately.",
"        <br>",
"         &sect; If amnionitis is suspected, broad-spectrum antibiotic therapy that includes an agent known to be active against GBS should replace GBS prophylaxis.",
"         <br>",
"          &Dagger; NAAT testing for GBS is optional and might not be available in all settings. If intrapartum NAAT is negative for GBS but any other intrapartum risk factor (delivery at &lt;37 weeks' gestation, amniotic membrane rupture at &ge;18 hours, or temperature &ge;100.4&deg;F [&ge;8.0&deg;C]) is present, then intrapartum antibiotic prophylaxis is indicated.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Verani JR, McGee L, Schrag SJ, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease - revised guidelines from CDC, 2010. MMWR Recomm Rep 2010; 59:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_63_33788=[""].join("\n");
var outline_f32_63_33788=null;
var title_f32_63_33789="Contents: Fetoplacental physiology";
var content_f32_63_33789=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?6/40/6798\">",
"       Obstetrics, Gynecology and Women's Health",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Fetoplacental physiology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Fetoplacental physiology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Amniotic fluid",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?30/52/31558\">",
"           Assessment of amniotic fluid volume",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/55/888\">",
"           Physiology of amniotic fluid volume regulation",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Fetal membranes",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/10/43175\">",
"           Fetal membranes: Anatomy and biochemistry",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Placenta",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/56/40840\">",
"           Gross examination of the placenta",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/46/27370\">",
"           Histopathology of placental disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/18/41256\">",
"           Placental development and physiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?21/26/21929\">",
"           Placental pathology in cases of neurologically impaired infants",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-BEC5BF95F2-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f32_63_33789=[""].join("\n");
var outline_f32_63_33789=null;
var title_f32_63_33790="Treatment of uncomplicated malaria";
var content_f32_63_33790=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F72019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F72019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for treatment of uncomplicated P. falciparum malaria (or species not identified)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_left\">",
"       Recommended drug and adult dose",
"      </td>",
"      <td class=\"subtitle1_left\">",
"       <p>",
"        Recommended drug and pediatric dose",
"       </p>",
"       <p>",
"        (pediatric dose should NEVER exceed adult dose)",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Chloroquine-resistant or unknown resistance*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"2\">",
"       All malarious regions except those specified as chloroquine-sensitive listed below. Middle Eastern countries with chloroquine-resistant",
"       <em>",
"        P. falciparum",
"       </em>",
"       include Iran, Oman, Saudi Arabia, and Yemen.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"2\">",
"       A. Artemisinin combination therapy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\" colspan=\"2\">",
"       <p>",
"        <strong>",
"         Artemether + lumefantrine (Coartem)",
"        </strong>",
"        &bull;",
"       </p>",
"       <p>",
"        Administration consists of combination tablets (1 tablet = 20 mg artemether and 120 mg lumefantrine). A 3 day treatment schedule with a total of 6 oral doses is recommended based on weight (5 - &lt;15 kg: 1 tablet per dose, 15 - &lt;25 kg: 2 tablets per dose, 25 - &lt;35 kg: 3 tablets per dose, &ge;35 kg: 4 tablets per dose). The patient should receive the initial dose, followed by the second dose 8 hours later, then 1 dose po bid for the following 2 days.",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\" colspan=\"2\">",
"       <p>",
"        <strong>",
"         Artesunate + amodiaquine",
"        </strong>",
"       </p>",
"       <p>",
"        Administration consists of separate scored tablets containing 50 mg of artesunate and 153 mg base of amodiaquine. The recommended treatment is 4 mg/kg of artesunate and 10 mg/kg of amodiaquine given once a day for 3 days.",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\" colspan=\"2\">",
"       <p>",
"        <strong>",
"         Artesunate + mefloquine",
"        </strong>",
"       </p>",
"       <p>",
"        Administration consists of separate scored tablets containing 50 mg of artesunate and 250 mg base of mefloquine, The recommended treatment is 4 mg/kg of artesunate given once a day for 3 days and 25 mg base/kg of mefloquine (usually split over 2 or 3 days to reduce vomiting and optimize absorption). This may be achieved either as 15 mg/kg (usually on the second day) followed by 10 mg/kg one day later, or as 8.3 mg/kg per day for 3 days.",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\" colspan=\"2\">",
"       <p>",
"        <strong>",
"         Artesunate + sulfadoxine-pyrimethamine",
"        </strong>",
"       </p>",
"       <p>",
"        Administration consists of separate scored tablets containing 50 mg of artesunate, and tablets containing 500 mg of sulfadoxine with 25 mg of pyrimethamine. The total recommended treatment is 4 mg/kg of artesunate given once a day for 3 days and a single administration of sulfadoxine-pyrimethamine (25/1.25mg base/kg) on day 1.",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\">",
"       B. Atovaquone-proguanil (Malarone)&bull;",
"      </td>",
"      <td class=\"subtitle3_left\">",
"       B. Atovaquone-proguanil (Malarone)&bull;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\" rowspan=\"2\">",
"       <p>",
"        Adult tab = 250 mg atovaquone/100 mg proguanil",
"       </p>",
"       <p>",
"        4 adult tabs po once daily x 3 days",
"       </p>",
"      </td>",
"      <td class=\"sublist2\">",
"       Adult tab = 250 mg atovaquone/100 mg proguanil",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       <p>",
"        Peds tab = 62.5 mg atovaquone/25 mg proguanil",
"       </p>",
"       <p>",
"        5-8 kg: 2 peds tabs po once daily x 3 days",
"       </p>",
"       <p>",
"        9-10 kg: 3 peds tabs po once daily x 3 days",
"       </p>",
"       <p>",
"        11-20 kg: 1 adult tab po once daily x 3 days",
"       </p>",
"       <p>",
"        21-30 kg: 2 adult tabs po once daily x 3 days",
"       </p>",
"       <p>",
"        31-40 kg: 3 adult tabs po once daily x 3 days",
"       </p>",
"       <p>",
"        &gt;40 kg: 4 adult tabs po once daily x 3 days",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\">",
"       C. Quinine sulfate",
"       <strong>",
"        PLUS",
"       </strong>",
"       one of the following: Doxycycline, Tetracycline, or Clindamycin",
"      </td>",
"      <td class=\"subtitle3_left\">",
"       C. Quinine sulfate&Delta;",
"       <strong>",
"        PLUS",
"       </strong>",
"       one of the following: Doxycycline&loz;, Tetracycline&loz;, or Clindamycin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Quinine sulfate: 542 mg base (=650 mg salt)&Delta; po tid x 3 or 7 days &sect;",
"      </td>",
"      <td class=\"sublist2\">",
"       Quinine sulfate: 8.3 mg base/kg (=10 mg salt/kg) po tid x 3 or 7 days &sect;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       <strong>",
"        PLUS",
"       </strong>",
"       one of the following:",
"      </td>",
"      <td class=\"sublist3\">",
"       <strong>",
"        PLUS",
"       </strong>",
"       one of the following:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Doxycycline: 100 mg po bid x 7 days",
"      </td>",
"      <td class=\"sublist2\">",
"       Doxycycline: 2.2 mg/kg po every 12 hours x 7 days",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Tetracycline: 250 mg po four times daily x 7 days",
"      </td>",
"      <td class=\"sublist2\">",
"       Tetracycline: 6.25 mg/kg po every 6 hours x 7 days",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Clindamycin: 20 mg base/kg/day (up to 1.8 grams) po divided tid x 7 days",
"      </td>",
"      <td class=\"sublist2\">",
"       Clindamycin: 6.7 mg base /kg  po every 8 hours x 7 days",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Sulfadoxine-pyrimethamine: single dose of 25/1.25 mg base/kg on day 1.",
"      </td>",
"      <td class=\"sublist2\">",
"       Sulfadoxine-pyrimethamine: single dose of 25/1.25 mg base/kg on day 1.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\" colspan=\"2\">",
"       D. Mefloquine (Lariam and generics) &yen;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\" colspan=\"2\">",
"       <strong>",
"        Mefloquine + artesunate",
"       </strong>",
"       (dosing as above)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\" colspan=\"2\">",
"       <strong>",
"        Mefloquine +/- doxycycline",
"       </strong>",
"       &Dagger;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Mefloquine: 684 mg base (=750 mg salt) po as initial dose, followed by 456 mg base (=500 mg salt) po given 6-12 hours after initial dose. Total dose = 1250 mg salt.",
"      </td>",
"      <td class=\"sublist2\">",
"       Mefloquine: 13.7 mg base/kg (=15 mg salt/kg) po as initial dose, followed by 9.1 mg base/kg (=10 mg salt/kg) po given 6-12 hours after initial dose. Total dose = 25 mg salt/kg.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       <strong>",
"        PLUS",
"       </strong>",
"      </td>",
"      <td class=\"sublist3\">",
"       <strong>",
"        PLUS",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Doxycycline: 100 mg po bid",
"      </td>",
"      <td class=\"sublist2\">",
"       Doxycycline: 2.2 mg/kg po every 12 hours",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"2\">",
"       Chloroquine-sensitive",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"2\">",
"       Central America west of Panama Canal; Haiti; the Dominican Republic; and most of the Middle East. Infections acquired in Korea and the states of the former Soviet Union have been uniformly caused by",
"       <em>",
"        P. vivax",
"       </em>",
"       to date and should therefore be treated as chloroquine-sensitive infections.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\">",
"       Chloroquine (Aralen and generics)",
"      </td>",
"      <td class=\"subtitle3_left\">",
"       Chloroquine (Aralen and generics)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       600 mg base (=1000 mg salt) po immediately, followed by 300 mg base (=500 mg salt) po at 6, 24, and 48 hours. Total dose: 1500 mg base (=2500 mg salt).",
"      </td>",
"      <td class=\"sublist2\">",
"       10 mg base/kg po immediately, followed by 5 mg base/kg po at 6, 24, and 48 hours. Total dose: 25 mg base/kg.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist3\">",
"       <strong>",
"        OR",
"       </strong>",
"      </td>",
"      <td class=\"sublist3\">",
"       <strong>",
"        OR",
"       </strong>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle3_left\">",
"       Hydroxychloroquine (Plaquenil and generics)",
"      </td>",
"      <td class=\"subtitle3_left\">",
"       Hydroxychloroquine (Plaquenil and generics)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       620 mg base (=800 mg salt) po immediately, followed by 310 mg base (=400 mg salt) po at 6, 24, and 48 hours. Total dose: 1550 mg base (=2000 mg salt).",
"      </td>",
"      <td class=\"sublist2\">",
"       10 mg base/kg po immediately, followed by 5 mg base/kg po at 6, 24, and 48 hours. Total dose: 25 mg base/kg.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     po: orally; bid: twice daily; tid: three times daily.",
"     <br>",
"      * NOTE: There are 4 options (A, B, C, or D) available for treatment of uncomplicated malaria caused by chloroquine-resistant P. falciparum. The US Centers for Disease Control (CDC) recommends options A (artemether-lumefantrine), B, and C equally. The World Health Organization (WHO) recommends option A as the first line treatment for uncomplicated malaria. For option C, because there is more data on the efficacy of quinine in combination with doxycycline or tetracycline, these treatment combinations are generally preferred to quinine in combination with clindamycin. In addition, option C has higher incidence of adverse effects than options A or B. Because of a higher rate of severe neuropsychiatric reactions seen at treatment doses, option D (mefloquine) is recommended only when the other options cannot be used.",
"      <br>",
"       &bull; Take with food or whole milk. If patient vomits within 30 minutes of taking a dose, then they should repeat the dose. It is also acceptable to take one half of the dose twice daily.",
"       <br>",
"        &Delta; US manufactured quinine sulfate capsule is only available in a 324 mg (salt) strength; therefore 2 capsules should be sufficient for adult dosing. Pediatric dosing may be difficult due to unavailability of non-capsule forms of quinine in the United States.",
"        <br>",
"         &loz; Doxycycline and tetracycline are not indicated for use in children less than 8 years old. For children less than 8 years old with chloroquine-resistant",
"         <em>",
"          P. falciparum",
"         </em>",
"         , atovaquone-proguanil and artemether-lumefantrine are recommended treatment options; mefloquine can be considered if no other options are available. For children less than 8 years old with chloroquine-resistant",
"         <em>",
"          P. vivax",
"         </em>",
"         , mefloquine is the recommended treatment. If it is not available or is not being tolerated and if the treatment benefits outweigh the risks, atovaquone-proguanil or artemether-lumefantrine should be used instead.",
"         <br>",
"          &sect; For infections acquired in Southeast Asia, quinine treatment should continue for 7 days. For infections acquired elsewhere, quinine treatment should continue for 3 days.",
"          <br>",
"           &yen; Treatment with mefloquine is not recommended in persons who have acquired infections from Southeast Asia due to drug resistance.",
"           <br>",
"            &Dagger; Treatment with mefloquine as a single agent is acceptable in low endemic areas as the likelihood of spread and maintenance of drug resistant parasites is low. However, in highly endemic areas combination therapy is important to prevent emergence of resistance.",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from United States Centers for Disease Control guidelines for treatment of malaria: file://www.cdc.gov/malaria/pdf/treatmenttable.pdf (Accessed June 18, 2009). CDC Malaria Hotline: (770) 488-7788 Monday-Friday 8 am to 4:30 pm EST - (770) 488-7100 after hours, weekends and holiday.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_63_33790=[""].join("\n");
var outline_f32_63_33790=null;
var title_f32_63_33791="Apley scratch tests for shoulder motion";
var content_f32_63_33791=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1124px;\">",
"  <div class=\"videoplayer\" h264=\"./images/EM/82878/Apley_scratch_tests_video.mp4?title=Apley+scratch+tests+for+shoulder+motion\" style=\"width:480px;height:288px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Apley scratch tests for shoulder motion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Apley &ldquo;scratch&rdquo; tests can provide an easy and reproducible way to assess shoulder motion. However, they should be performed as an adjunct to standard range of motion tests as they do not adequately assess all shoulder movements.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Simons, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_63_33791=[""].join("\n");
var outline_f32_63_33791=null;
